Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents

Octavian Vasiliu *
Department of Psychiatry, Dr. Carol Davila University Emergency Central Military Hospital, Bucharest, Romania

Many investigational drugs with antidepressant activity are currently explored in different phases of clinical research, with indications such as major depressive disorder, treatment-resistant major depression, bipolar depression, post-partum depression, and late-life depression. Although the vast majority of the antidepressants in clinical use are based on the monoaminergic hypothesis of depression, recent data supported the launching on the market of two new, non-monoamine-modulating drugs. Esketamine for treatment-resistant major depression and brexanolone for post-partum depression are two exceptions from the monoaminergic model, although their use is still limited by high costs, unique way of administration (only intravenously for brexanolone), physicians’ reluctance to prescribe new drugs, and patients’ reticence to use them. Glutamatergic neurotransmission is explored based on the positive results obtained by intranasal esketamine, with subanesthetic intravenous doses of ketamine, and D-cycloserine, traxoprodil, MK-0657, AXS-05, AYP-786, combinations of cycloserine and lurasidone, or dextromethorphan and quinidine, explored as therapeutic options for mono- or bipolar depression. Sestrin modulators, cholinergic receptor modulators, or onabotulinumtoxinA have also been investigated for potential antidepressant activity. In conclusion, there is hope for new treatments in uni- and bipolar depression, as it became clear, after almost 7 decades of monoamine-modulating antidepressants, that new pathogenetic pathways should be targeted to increase the response rate in this population.

Keywords: treatment-resistant depression, bipolar depression, esketamine, brexanolone, glutamate, onabotulinumtoxinA

INTRODUCTION

Major depressive disorder (MDD) has a significant functional impact on patients’ psychosocial functioning and quality of life (Fried and Nesse, 2014). Also, individual symptoms of depression, especially sad moods and concentration problems, are associated with high levels of dysfunction in daily activities, based on an analysis of data from the STAR*D trial (Sequenced Treatment Alternatives to Relieve Depression) (Fried and Nesse, 2014). Almost 60% of individuals diagnosed with MDD report severe or very severe impairment of functioning (Kessler et al., 2003). A significant proportion of patients diagnosed with MDD will have treatment-resistant forms (TRD), which associate high direct and indirect costs, and those patients who could not reach
remission have considerable healthcare resource utilization, with significant economic impact (Petrescu et al., 2014; Heerlein et al., 2022).

Patients diagnosed with bipolar disorder also may develop significant functional impairment (due to direct effects of illness severity, cognitive impairments, psychiatric comorbidities, etc.), and they spend a large duration of their lives in depressive episodes or recovering from these episodes (Levy and Manive, 2012; Solomon et al., 2016).

Postpartum depression affects up to 15% of mothers, and its short-term and long-term negative consequences on child development are well-established (Pearlstein et al., 2009). Few therapeutic options are validated for this specific pathology, and fear in mothers related to breastfeeding during antidepressant administration is a significant obstacle to efficient therapeutic management (Pearlstein et al., 2009).

Another difficult-to-treat type of mood disorder is late-life depression, where vascular factors and psychological and social factors are intertwined, and a significant risk of completed suicide is also a major threat (Vasiliu and Vasile, 2016; Alexopoulos, 2019).

New antidepressants that could be administered either as monotherapy or as an add-on to the ongoing treatment in the case of partial/inadequate response are urgently needed in clinical practice. Glutamatergic and cholinergic drugs targeting components of the hypothalamic-pituitary-adrenal axis and other non-monoaminergic systems are currently under investigation in clinical research. The main objective of this review is to explore new investigational products with antidepressant properties and their reported efficacy and tolerability in depressive disorders.

**METHODOLOGY**

A systematic review of the articles referring to new drugs in phases I to III of clinical studies was conducted through the main electronic databases (PubMed, MEDLINE, Cochrane, Web of Science (Core Collection), PsychINFO, Scopus, and EMBASE using the paradigm “investigational antidepressants/products” OR “new antidepressants/agents” AND “clinical trial” AND “major depressive disorder” OR “bipolar disorder” OR “depression.” Lists of references for every article corresponding to the search paradigm were investigated, and they were added to the review if they were not detected through the previously mentioned paradigm.

A broad search was chosen to include the widest variety of molecules. For this purpose, a supplementary search was added, targeting investigational products for depression explored in the clinical trials repositories run by the United States National Library of Medicine and the National Institutes of Health (clinicaltrials.gov), World Health Organization (International Clinical Trials Registry Platform), and European Union (EU Clinical Trial Register). The search within the clinical trial databases was structured by the disorder, “depression”; type, “interventional”; population, “adults”; and “adolescents,” and trial phases I to III, but all statuses of recruitment were allowed. If the outcome of a registered trial for an investigational product was not mentioned in any of the mentioned repositories, the respective drug manufacturer’s site was explored to verify if any results were available.

All articles and references from electronic databases and clinical studies repositories included were allowed in the primary search if they were published between January 2000 and February 2022.

This systematic review is based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, and all the data collection, review, reporting, and discussion were conducted according to this statement (Figure 1) (Moher et al., 2015). Inclusion and exclusion criteria are mentioned in Figure 4.

All pharmacological agents included in the collected data were grouped into nine categories: monoamine-based drugs, orexin receptor modulators, GABA-A receptor modulators, neurosteroid analogs, anti-inflammatory therapies, glutamatergic antidepressants, sestrin modulators, cholinergic agents, combinations of agents, and a residual category for all other molecules with distinct mechanisms of action. The first four categories of agents have been described in the first part of this review.

**RESULTS**

The results of the PRISMA-based search paradigm are presented in Figure 2. Glutamatergic agents are the most extensively researched category of antidepressants, and 29 different molecules have been found in 72 distinct sources (Table 1). Thirteen phase I studies, two phase I/II trials, 30 phase II trials, one phase II/III trial, seven phase III trials, five phase IV trials, and eight not assessed for clinical phase trials were reviewed in this category.

Sestrin modulators were identified in two sources referring to one phase I and one phase II trials, assessing a single agent from this category. Four different combinations of pharmacological agents were identified in 13 sources, referring to 5 phase II trials, 8 phase III trials, and one not assessed for a clinical phase trial.

Cholinergic antidepressants have been identified in 10 distinct sources, referring to three investigational products, explored in two phase I trials, four phase II trials, two phase IV trials, and two not assessed for clinical phase trials. Eight other antidepressants with distinct mechanisms of action have been identified in 13 sources, referring to one phase I trial, seven phase II trials, two phase IV trials, and three not assessed for clinical phase trials.

All agents identified through this database search are presented in Figure 3.

**Glutamatergic Agents**

Traxoprodil (CP-101,606) is a potent, selective antagonist of the GluN2B subunit within the NMDA receptor, with the capacity to
potentiate the antidepressant-like effects of certain drugs in animal models (Poleszak et al., 2016). Traxoprodil inhibits the channel activity of subunits GluN1/GluN2B and reduces the time and frequency of its opening, thus preventing an excessive influx of calcium ions into neurons and secondary damage (Poleszak et al., 2016). Traxoprodil exhibited antidepressant activity in the forced swim test in rats (an animal model to screen molecules with antidepressant effect), and co-administration of traxoprodil with imipramine, fluoxetine, or escitalopram, each in subtherapeutic doses, affected at a significant level the pseudo-depressive behavior in this model (Poleszak et al., 2016).

In patients with TRD (defined by lack of response to at least one adequate trial of a selective serotonin reuptake inhibitor, SSRI), CP-101,606 was administered in a randomized, placebo-controlled, double-blind study (Preskorn et al., 2008). During the first phase of the study, subjects received a 6-week open-label administration of paroxetine and single-blind i.v. placebo infusion, with non-responders being randomized in the second phase to a double-blind single infusion of CP-101,106 or placebo plus treatment with paroxetine for up to an additional 4 weeks (Preskorn et al., 2008). The main outcome (Montgomery Asberg Depression Rating Scale, MADRS score on day 5 during the second phase) differentiated the active drug from the placebo (Preskorn et al., 2008). The response rate on Hamilton Depression Rating Scale (HAM-D) was 60% versus 20% for traxoprodil versus placebo, and 78% of these active drug responders maintained their response for at least 1 week after the infusion (Preskorn et al., 2008). The antidepressant response was possible without producing significant dissociative reactions, with overall good tolerability (Preskorn et al., 2008).

A randomized, placebo-controlled, crossover pilot trial evaluated the efficacy and tolerability of the orally administered, selective GluN2B antagonist rislenemdaz (MK-0657) in patients with TRD (N = 5 participants) (Ibrahim et al., 2012). After 1 week drug-free period, subjects were randomized to receive either MK-0657 monotherapy (4–8 mg/day) or placebo for 12 days (Ibrahim et al., 2012). Significant antidepressant effects were reported as early as day 5 in patients receiving active drug versus placebo, as reflected by the evolution of the HAMD and Beck Depression Inventory (BDI) scores, but no improvement was observed on the MADRS, the primary efficacy measure (Ibrahim et al., 2012). The tolerability was good, without dissociative adverse events in patients receiving MK-0657 (Ibrahim et al., 2012).

EVT-101 is another orally administered, potent, and selective glutamate GluN2B antagonist (Strobel et al., 2016). A phase II, randomized, double-blind, parallel-group, 4-week study was designed to evaluate the efficacy of EVT-101 in patients with TRD (after the confirmation of treatment resistance in a prospective treatment period with citalopram) but was prematurely terminated because a clinical hold was issued by FDA (NLM, NCT01128452). AGN-241751 is an orally active, NMDA-receptor positive allosteric modulator, currently tested as an antidepressant in clinical trials, although its precise mechanism of action and specific NMDA subunit for which it is ligand is still unknown (Pothula et al., 2021). AGN-241751 reverses behavioral deficits induced by chronic unpredictable stress in mice and possesses antidepressant-like properties in animal models (Pothula et al., 2021).
signaling, and increased level of the synaptic proteins responsible for synaptic plasticity in the prefrontal cortex (Pothula et al., 2021). Also, according to the same study on mice, GluN2B subunits from the excitatory neurons in the prefrontal cortex are the initial cellular trigger underlying antidepressant effects of AGN-241751 (Pothula et al., 2021).

A two-part, double-blind, placebo-controlled, single and multiple-dose (part A) or twice-daily dose (part B), phase I/II trial conducted with adult participants (N = 223) diagnosed with MDD was completed in 2019 (NLM, NCT03726658). Both parts of the trial used an efficacy measure, the MADRS score, and the primary outcome was the change in this score on day 1 and day 7 after the administration of AGN-241751 (NLM, NCT03726658). No results have yet been posted as of February 2022. Another randomized, double-blind, placebo-controlled, fixed-dose, phase II trial included 251 adult participants diagnosed with MDD and evaluated the efficacy at day 1 after the initial dose of AGN-241751, defined by MADRS score change (NLM, NCT03586427). No results have been published from this trial, either.

MIJ821 is a glutamate GluN2B antagonist investigated in a proof-of-concept, randomized, subject and investigator-blinded, parallel-group, placebo-controlled study on patients with TRD (N = 70 participants) (Ghaemi et al., 2021). Low dose and high dose infusions of MIJ821 (0.16 mg/kg weekly or bi-weekly versus 0.32 mg/kg weekly or bi-weekly) were compared to placebo (weekly) and ketamine infusion (0.5 mg/kg weekly) at 24 h, 48 h, and 6 weeks, the primary outcome measure being the change in the MADRS scores (Ghaemi et al., 2021). The adjusted mean differences versus placebo were significant for all MIJ821 dosing regimens and ketamine at 24 and 48 h (Ghaemi et al., 2021). At 6 weeks, none of the active interventions retained their statistical significance by comparison to placebo (Ghaemi et al., 2021).

Another double-blind, randomized, placebo-controlled, dose-ranging, phase II trial is ongoing, its objective being the investigation of efficacy and safety of intravenous MIJ821 infusion in addition to comprehensive standard of care (SOC) in patients with MDD and suicidal ideation with intent (NLM, NCT04722666). This study consists of three periods: a screening phase (up to 48 h), a double-blind core period (6 weeks), and an extension period (up to 52 weeks). It will enroll an estimate of 195 patients (NLM, NCT04722666).

Dextromethadone (d-methadone, esmethadone, REL-1017) has low micromolar affinity at GluN2 subunits (2A-2D) of the NMDA receptors, with a slightly superior affinity for GluN2B subunit (Callahan et al., 2004; Fogaça et al., 2019). Dextromethadone also has a very low affinity for the μ and δ-opioid receptors and does not produce opioid-like effects in humans at doses predicted to induce antidepressant activity (Fogaça et al., 2019). In a multicenter, randomized, double-blind, placebo-controlled, phase IIa trial, two dosages of REL-1017 (25 or 50 mg orally daily) were compared to placebo (N = 21, 19, and 22 participants, respectively) to assess the efficacy and tolerability of this product in patients with MDD who did not improve after 1–3 standard antidepressant treatments (Fava et al., 2022). Patients experienced mild or moderate adverse events during the 7 days of the trial, with no evidence of dissociative or psychotomimetic effects, opioid effects, or withdrawal signs.
### TABLE 1 | Glutamatergic agents with antidepressant properties in the pipeline.

| Authors | GluN2B antagonists | Methodology | Results | Clinical trial phase, trial identifier (if available) |
|---------|---------------------|-------------|---------|------------------------------------------------------|
| Preskorn et al. (2008) | Traxoprodil (ICP-101,606), 6-week open-label + 4-week DBRCT, N = 30 MDD non-responders to open-label phase | MADRS score on day 5 (main outcome) significantly differentiated the active drug from the placebo. The response rate on HAMD was 60 vs. 20% for traxoprodil vs. placebo. The overall tolerability was good | Phase II, NCT00163059 |
| Ibrahim et al. (2012) | Rilsenemdz (MK-0657), N = 5 TRD patients, 12 days | Significant antidepressant effects were reported as early as day 5 in patients receiving active drug vs. placebo (HAMD and BDI scores), but no improvement was observed on the MADRS (the primary efficacy measure). The tolerability was good, without dissociative AE in patients receiving MK-0657 | Phase I, NCT00472576 |
| NLM (2010a) | EVT-101, DBRCT, N = 8 TRD patients, 4 weeks | The primary outcome measure is the safety and tolerability profile of EVT-101. The study was prematurely discontinued due to a clinical hold issued by FDA. | Phase II, NCT01128452 |
| NLM (2018a) | AGN-241751, two-part DBRCT, N = 233 MDD patients, 7 days | The primary outcome was the change in this score on day 1 and day 7 after the administration of AGN-241751. No results were posted as of February 2022 | Phases II/III, NCT03726658 |
| NLM (2018b) | AGN-241751, DBRCT, N = 251 MDD patients, 24 h | The efficacy at day 1 after the initial dose of AGN-241751, defined by MADRS score change, was the primary outcome. No results have yet been posted | Phase II, NCT03556427 |
| Ghaemi et al. (2021) | Low dose/ high dose MUB21 vs. placebo vs. ketamine, DBRCT, N = 70, TRD patients, 6 weeks | The adjusted mean differences vs. placebo were significant for all MUB21 dosing regimens and ketamine at 24 and 48 h. At 6 weeks, none of the active interventions retained their statistical significance vs. placebo | Phase II, NCT02736129 |
| NLM (2021a) | MUB21 + comprehensive SOC, dose-ranging, N = 195 patients MDD + suicidal ideation/intent (estimated), 52 weeks | Primary outcome measure, MADRS total score at 24 after the first infusion and up to 52 weeks. Secondary outcomes, treatment-emergent AE (number and severity), pharmacokinetics, response rate, sustained response rate, remission rate, sustained remission rate | Phase II, NCT04722666 |
| Fava et al. (2022) | High-dose/low-dose dextromethadone (REL-1017) adjunctive to ongoing antidepressant treatment, DBRCT, N = 62 TRD patients, 7 days | Patients experienced mild or moderate AE during the 7 days of the trial, with no evidence of dissociative or psychotomimetic/oral/withdrawal signs. MADRS scores improved on day 4 in both REL-1017 groups and persisted up to 14 days | Phase IIa, NCT03051256 |
| NLM (2021b) | REL-1017 adjunctive to antidepressant treatment, two DBRCT, N = 400 MDD patients for each trial (estimated enrolment), 28 days | The primary outcome measure is MADRS total score change from baseline to day 28. These trials are ongoing as of February 2022 | Phase III, NCT04688164, Phase III, NCT04855747 |
| NLM (2021c) | REL-1017 as monotherapy, DBRCT, N = 400, MDD, 28 days | The primary outcome measure is MADRS total score change from baseline to day 28. The trial is ongoing | Phase III, NCT05081167 |
| NLM (2021d) | REL-1017 as adjunctive to current antidepressant treatment, open-label, N = 600 MDD patients (estimated enrolment), 52 weeks | MADRS total score change from baseline to week 52 is the primary outcome. This trial is ongoing as of February 2022 | Phase III, NCT04855760 |
| Agbo et al. (2017) | AZD6765 (lancemine), open-label and DBRCT, respectively, N = 46 and 40, respectively, healthy subjects, 6 days | Pharmacokinetic analysis was performed by non-linear mixed-effects modeling. The population pharmacokinetic model adequately described the clinical observation of lancemine in healthy volunteers | Phase I, NCT01069822 Phase I, NCT00785915 |
| Agbo et al. (2017) | AZD6765, DBRCT, single dose or multiple infusion, respectively, N = 34 and 152, respectively, treatment-resistant MDD patients, 24 h and 3 weeks, respectively | Pharmacokinetics parameters were already mentioned above. The overall tolerability of 100 mg lancemine was good, and an antidepressant effect was detected after single-dose infusion, peaked at 72 h, and dissipated vs. placebo by 10–13 days. In the multiple-dose trial, 100 and 150 mg lancemine were compared to placebo, and MADRS total score changed significantly at week 3 in the active drug groups. Most secondary outcomes (HAMA, QIDS-SR, Q-LES-Q) supported the significant improvement in MADRS at week 3 in the 100 mg lancemine group | Phase IIa, NCT00491686 Phase IIb, NCT00781742 |
| Sanacora et al. (2017) | AZD6765 (50/100 mg) adjunctive to ongoing antidepressant treatment, DBRCT, N = 302 MDD patients with inadequate response to treatment, 12 weeks | Lancemine was generally well-tolerated, but neither dose was superior to placebo in decreasing the severity of the depressive symptoms (MADRS total score, QIDS-SR, SDS, CGI) | Phase IIb, NCT01482221 |
| Zarate et al. (2013) | AZD6765 (150 mg), DBRCT, N = 22 TRD patients, 7 days | MADRS score significantly improved, within 80 min, in subjects receiving AZD6765 compared to placebo, and this improvement remained significant only through 110 min. The HAMD scores reflected an effect between groups at 80 and 110 min and also on day 2. The response rate was 52% in the AZD6765-treated group vs. 15% in placebo-treated patients. No difference between groups was reported in the rate of psychotomimetic and dissociative AE | Phase II, NCT00986479 |
| AMPA receptor potentiators | TAK-653, five escalating doses vs. placebo, three-crossover phases, DBRCT, N = 24 healthy volunteers, three phases of 1 day each, separated by wash-out periods of 10–15 days | This investigational product did not affect resting motor threshold or paired-pulse responses in humans, determined by cortical sp/ ppTMS | Phase I, NCT03792672 |
| O'Donnell et al. (2021) | TAK-653, escalating single and multiple doses vs. placebo, N = 88 healthy volunteers, 14 ± 31 days | The overall tolerability of the investigational product was good; no SAE were reported | Phase I, NCT02561156 |

(Continued on following page)
### TABLE 1 (Continued) Glutamatergic agents with antidepressant properties in the pipeline.

| Authors | Methodology | Results | Clinical trial phase, trial identifier (if available) |
|---------|-------------|---------|------------------------------------------------------|
| NLM (2017a) | TAK-653, DBRCT, TRD patients, 57 days | The primary outcome was time to relapse (MADRS total score). The study was withdrawn (business decision). No subject has been reported as enrolled in this trial | Phase II, NCT0312894 |
| NLM (2021a) | (2R,3R)-Hydroxy-ketamine, DBRCT, MAD, N = 48 (estimated) healthy volunteers, 8 or 19 days (GAD, and MAD, respectively) | Primary outcome measures are related to safety and tolerability. The trial is ongoing as of February 2022 | Phase I, NCT04711005 |
| NVMDA-receptor antagonist | | | |
| NLM (2016) | NRX-101 vs. lurasidone after stabilization on ketamine, DBRCT, four-arm trial, N = 22 BD patients + suicidal ideation/behavior, 42 days | The results support the superior efficacy of the ketamine followed by NRX-101 vs. ketamine followed by lurasidone treatment, as reflected by the BDM scores. No SAE were reported in any of these trial arms, and no significant difference in the rate of AE was observed between NRX-101 and lurasidone-treated groups | Phase II, NCT02974010 |
| NLM (2018a) | NRX-101 vs. lurasidone after stabilization on ketamine, DBRCT, N = 72 (estimated) BD patients + suicidal ideation/behavior, 6 weeks | The main outcome of this trial is the improvement in the depressive symptoms between NRX-101 and lurasidone as measured by the MADRS total score. This trial is ongoing Phase II, NCT0396068 |
| NLM (2018b) | NRX-101 vs. lurasidone, N = 24 (estimated) moderate severity BD patients + suicidal ideation, 6 months | The primary outcome is the C-SSRS score. This trial is ongoing Phase Iii, NCT03402152 |
| NLM (2018c) | NRX-100 vs. placebo, DBRCT, N = 150 (estimated) BD patients + suicidal ideation/behavior, 24 h | | |
| NLM (2018d) | AV-101 vs. placebo, cross-over DBRCT, N = 19 TRD patients, multiple time frames | | |
| Park et al. (2020) | AV-101 vs. placebo, cross-over DBRCT, 4/5 h | No treatment effects were detected using linear mixed models, as determined by primary (HAMD score) or secondary (C-SSRS, response/remission rate) outcome measures. No differences for AE were reported at any time between groups | Phase II, NCT02484456 |
| Murphy et al. (2021) | AV-101 9720/1440 mg i.v. vs. placebo, cross-over DBRCT, 4/5 h | Only the high dose (1440 mg) of AV-101 in humans succeeded in engaging brain targets in humans Phase Iii, NCT03583554 |
| Preskorn et al. (2015) | Rapastinel (GLYX-13), single-dose, 1, 5, 10, or 30 mg/kg vs. placebo, DBRCT, N = 116 MDD patients with inadequate/partial response to antidepressants, 16 weeks | The effect of GLYX-13 was significant vs. placebo on day 7, but not different on day 14 on HAMD-17. Reductions in HAMD were most important for 5 and 10 mg/kg. No treatment-related SAE occurred during the study Phase II, NCT01234558 |
| Moskal et al. (2014), Preskorn et al. (2015) | GLYX-13 vs. placebo, DBRCT, N = 53, healthy volunteers, 4 weeks | Pharmacokinetic parameters were described after a single i.v. dose administration (0.5–2.5 mg/kg) Phase I, NCT01014650 |
| NLM (2012a) | GLYX-13 (5 or 10 mg/kg) vs. placebo, DBRCT, N = 369 MDD patients with inadequate/partial response to antidepressants, 16 weeks | The primary outcome measure is HAMD total score change. The study was completed, but the results are not disclosed Phase Ii, NCT01684163 |
| NLM (2019a) | GLYX-13 (225/450 mg i.v.), open-label extension, N = 61 MDD patients with inadequate/partial response to antidepressants, 48 months | The primary outcome was the number of participants who experienced an AE during the trial. The study was terminated by the sponsor in 32 cases, and 11 participants withdrew. Patients were enrolled in NCT03666600, but this trial was also terminated (business decision) Phase Ii, NCT02192099 |
| NLM (2013) | Aripiprazole (INRX-107-6) vs. placebo, DBRCT, MAD, N = 100 healthy volunteers, 28 days | The primary outcome was observed and laboratory-confirmed safety. Undisclosed results Phase I, NCT01856556 |
| NLM (2015b) | NRX-1074 375/500/750 mg orally administered vs. placebo, DBRCT, MAD, N = 15 healthy volunteers, 28 days | The primary outcomes were related to safety and tolerability. Undisclosed results Phase I, NCT02366364 |
| Brooks (2015) | NRX-1074 vs. placebo, DBRCT, N = 140 MDD patients, 14 days | The primary outcome was the HAMD-17 total score change. Improvement reported after one dose of NRX-1074 infusion had an effect size of 0.88. It was also observed that 72% of the patients receiving the highest of the three tested doses demonstrated a clinically meaningful response at 24 h vs. 39% in the placebo group Phase II, NCT02067793 |
| NLM (2015c) | Ketamine i.v. (single infusion) 0.1/0.25/0.5 mg/kg vs. midazolam 0.03 mg/kg (active placebo), DBRCT, N = 33 late-Lie TRD patients, 28 days | The rate of response (50% reduction on MADRS total score) at day 7 was 72.7% for 0.5 mg/kg ketamine i.v. vs. 46.2% for midazolam (active placebo) and 87.5 vs. 66.7% at day 28 Phase III, NCT02556606 |
| NLM (2017b) | Ketamine 0.5 mg/kg vs. placebo, DBRCT, N = 64 prenatal depression patients, 48 h | EPDS score at 48 h after delivery is the main outcome measure. Undisclosed results Phase IV, NCT03336541 |
| Lapidus et al. (2014) | Intranasal ketamine (SLS-002) vs. placebo, cross-over DBRCT, N = 20 TRD patients, 24 h | Patients treated with SLS-002 significantly improved their depressive symptoms 24 h after drug administration vs. placebo (MADRS total score change), and the overall tolerability was good, with minimal AE. Response criteria were met by 8 out of the 18 patients treated with ketamine 24 h after drug administration vs. 1 out of 8 patients on placebo Phase II, NCT01304147 |
| NLM (2020), PRNewswire (2021a) | SLS-002 + SOC, N = 236 (estimated) MDD patients with imminent risk of suicide, two phases: the first phase is open-label, while the second is double-blind, 24 h and 16 days, respectively | The main MADRS score changed significantly, with 20.3 points in 24 h, and no clear dissociative symptoms were reported Phase I, NCT04669665 |
| Leal et al. (2021) | R-Ketamine (PCN-101), open-label, pilot trial, N = 7 TRD patients, 24 h | | (Continued on following page)
### TABLE 1 (Continued) Glutamatergic agents with antidepressant properties in the pipeline.

| Authors Methodology | Clinical trial phase, trial identifier (if available) |
|---------------------|------------------------------------------------------|
| **GluN2B antagonists** |                                                      |
| PRNewswire (2021b) PCN-101 vs. placebo, DBRCT, N = 58 healthy volunteers | Phase I, ACTRN12620000226909 |
| Huang et al. (2013), NLM (2009a) N-Methylglycine (sarcosine) vs. citiopram, DBRCT, N = 40 MDD patients, 6 weeks | Phase II, NCT00977353 |
| PRNewswire (2021b) PCN-101 vs. placebo, DBRCT, N = 58 healthy volunteers | Phase IV, NCT04975100 |
| Heresco-Levy et al. (2008) D-Cycloserine vs. placebo as add-on to ongoing antidepressant, cross-over DBRCT, N = 22 TRD patients, 6 weeks | Phase I |
| Heresco-Levy et al. (2013) D-Cycloserine vs. placebo as add-on to ongoing antidepressant, DBRCT, N = 26 TRD patients, 6 weeks | Phase II |
| Chen et al. (2019) D-Cycloserine, N = 32 MDD or BD patients who responded to ketamine i.v. in an open-label first phase, DBRCT, 6 weeks | Phase II |
| NLM (2018f) D-Cycloserine vs. modafinil + CBT, DBRCT, N = 36 MDD patients, 3 weeks | Phase II |
| Chen et al. (2014) Dextromethorphan/placebo + valproic acid, DBRCT, N = 309 BD patients, 12 weeks | Phase N/A |
| Nagele et al. (2015) Nitrous oxide vs. placebo, cross-over DBRCT, N = 21 TRD and non-TRD patients, 24 h | Phase II |
| NLM (2017c) Nitrous oxide vs. placebo, DBRCT, N = 34, 24 h | Phase II, NCT02376257 |
| Zarate et al. (2004) Riluzole 168.8 mg/day, open-label trial, N = 19 TRD patients, 6 weeks | Phase N/A |
| Brennan et al. (2010) Riluzole 100–200 mg/day, open-label trial, N = 14 BD patients, 6 weeks | Phase N/A, NCT00544544 |
| Sanacora et al. (2007) Riluzole 100 mg/day + ongoing antidepressant, open-label trial, N = 10 TRD patients, 6 + 6 weeks | Phase N/A |
| NLM (2013b) Riluzole/placebo + ongoing SSRI/SNRI, DBRCT, N = 104 TRD patients, three-phase study (24 weeks, in total) | Phase II, NCT01204918 |
| NLM (2012b) Riluzole + sertraline vs. placebo + sertraline, DBRCT, N = 21 MDD outpatients, 8 weeks | Phase II, NCT01703039 |
| NLM (2001) Riluzole 50–200 mg/day, single-arm, single-blind, N = 31 MDD patients, 6 weeks | Phase II, NCT0026052 |
| Mathew et al. (2010) Lamotrigine vs. placebo pre-treatment, followed by ketamine infusion, responders were randomized on riluzole 100-200 mg/ day or placebo, DBRCT, N = 26 recurrent or chronic MDD, 24–72 h after i.v. ketamine | Phase IV, NCT00419003 |

(Continued on following page)
TABLE 1 | (Continued) Glutamatergic agents with antidepressant properties in the pipeline.

| Authors | Methodology | Results | Clinical trial phase, trial identifier (if available) |
|---------|-------------|---------|--------------------------------------------------|
| NLM (2006a) | Riluzole 100–200 mg/day vs. placebo, DBRCT, N = 94 BD patients, 8 weeks | The primary outcome was the change in the MADRS score. The rough, unpublished results did not support the superior efficacy of riluzole vs. placebo | Phase II, NCT00376220 |
| Zarate et al. (2005) | Riluzole 50–200 mg/day + lithium, open-label study, N = 14 BD patients, 8 weeks | The linear mixed model for total MADRS score showed a significant treatment effect at week 6, without cases of switch into hypomania or mania | Phase II |
| NLM (2003) | Riluzole 50–200 mg/day vs. placebo, DBRCT, N = 19 BD patients, 8 weeks | The study was terminated due to the superior efficacy of placebo in an interim analysis | Phase II, NCT00054704 |
| Zarate et al. (2008) | Memantine 5–20 mg/day vs. placebo, DBRCT, N = 32 MDD patients, 8 weeks | The results of this trial (MADRS scores change from baseline to week 8) were negative | Phase N/A |
| Smith et al. (2013) | Memantine 5–20 mg/day vs. placebo + antidepressant, DBRCT, N = 31 MDD patients with partial or non-responsive MDD, 8 weeks | No statistical differences were observed between groups on primary or secondary efficacy outcomes or safety outcomes | Phase N/A |
| NLM (2006b) | Memantine 5–20 mg/day + lamotrigine, DBRCT, N = 29 BD patients, 8 weeks | The primary outcome was the change in HAMD-17 from baseline to week 8. Unpublished results show a decrease of 9 vs. 7 points in patients treated with memantine vs. placebo. The most frequently reported adverse events in the memantine group were somnolence, indigestion, diarrhea, headache, and coughing | Phase IV, NCT00305578 |
| NLM (2002) | Memantine 5–20 mg/day vs. placebo, DBRCT, N = 112 MDD outpatients, three-phase study (2, 8, and 16 weeks) | No results of this trial have been released | Phase III, NCT00042691 |
| NLM (2006c) | Memantine 5–20 mg vs. placebo as add-on to antidepressants, DBRCT, N = 31 MDD patients with incomplete response/non-response to antidepressants | The primary outcome was the change in MADRS scores at week 8. Unpublished results did not support a significant difference between groups (−7.13 vs. −7.25 points in memantine vs. placebo). The rate of serious adverse events was similar in the two groups | Phase IV, NCT00334682 |

Metabotropic glutamate receptors antagonists

| Authors | Methodology | Results | Clinical trial phase, trial identifier (if applicable) |
|---------|-------------|---------|--------------------------------------------------|
| Watanabe et al. (2021) | TP473692 (TS-161) vs. placebo, DBRCT, SAD, and MAD, N = 70 healthy subjects, 10 days | The investigational product penetrated the brain–blood barrier, and the most frequently reported AE were nausea, vomiting, and dizziness, with an exposure-related incidence | Phase I, NCT03919409 |
| NLM (2021g) | TS-161 vs. placebo, DBRCT, N = 25 (estimated), TRD patients, 21 days | The main outcome is the change from baseline to day 21 on MADRS total scores. The trial is ongoing | Phase II, NCT04821271 |
| Umbricht et al. (2020) | Decogulant (PO4996819) vs. placebo, DBRCT, N = 357 TRD patients, 6 weeks | At week 6, no significant differences were observed between any active treatment arms and placebo in decreasing MADRS scores, response, or remission rates. No effects of decogulant were observed on CANTAB. A high rate of placebo response was observed | Phase II, NCT01457677 |
| NLM (2012c) | RO6965819 vs. placebo as adjunctive therapy, DBRCT, TRD patients, 6 weeks | The primary outcome was the change in MADRS total score change. The trial was withdrawn by the sponsor. No subject was enrolled | Phase II, NCT01739654 |
| Quiroz et al. (2016) | Basimglurant (RG-7090) vs. placebo as an adjunctive agent to SSRI/SNRI, DBRCT, N = 333 MDD patients, 6 weeks | No difference was observed in the primary outcome, MADRS change from baseline to the endpoint, basimglurant MR and placebo. Secondary endpoints were modified by adjunctive basimglurant MR 1.5 mg daily, especially in patient-rated measures. The most frequently reported AE was dizziness, but it was of mild intensity and transient | Phase IIb, NCT01437667 |
| NLM (2015d) | RG-7090 vs. placebo, DBRCT, MAD, N = 56 healthy subjects + MDD patients, 10 weeks | The primary outcomes were tolerability and safety of the investigational product. The results of this trial are undisclosed as of February 2022 | Phase I, NCT02430393 |
| NLM (2010c) | AZD-2066 vs. placebo + duloxetine, DBRCT, N = 131 MDD patients, 6 weeks | The primary outcome was MADRS total core change from baseline to week 6. The improvement was −13.1 (AZD 2066), −14 (duloxetine), and −14.1 (placebo). The response rate was the same in all three groups | Phase IIa, NCT01145755 |

AE, adverse events; AMPA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; BD, bipolar depression; BDNf, brain-derived neurotrophic factor; CANTAB, Cambridge Neuropsychological Test Automated Battery; CBST, cognitive-behavioral therapy; CGI, Clinical Global Impression; C-SSRS, Columbia Suicidality Severity Scale; DBRCT, double-blind randomized controlled trial; FDA, Food and Drug Administration; GAF, Global Assessment of Functioning; HAMD, Hamilton Depression Rating Scale; MAD, multiple ascending dose; MADRS, Montgomery-Asberg Depression Rating Scale; MDD, major depressive disorder; N/A, not applicable; NIMH, National Institute of Mental Health; NINDS, N-methyl-D-aspartate; Q-LES-Q, Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form; SAD, single ascending dose; SAE, severe adverse events; SDS, Sheehan Disability Score; SNRI, serotonin and norepinephrine reuptake inhibitor; SOC, standard of care; SSRI, selective serotonin reuptake inhibitors; sp/pTMS, single-pulse/paired-pulse transcranial magnetic stimulation; TRD, treatment-resistant MDD.

and symptoms (Fava et al., 2022). MADRS scores improved on day 4 in both REL-1017 dosage groups, and this change persisted through the follow-up visit (day 14) (Fava et al., 2022).

Two phase III, multicenter, double-blind, placebo-controlled outpatient trials are ongoing, and they have as objective the assessment of the efficacy and safety of REL-1017 as an adjunctive treatment of MDD (RELIANCE-I, II) (NLM, NCT04688164). The estimated enrollment in these trials is estimated to be 400 participants, who will be monitored for 28 days, with changes in MADRS total score as the main outcome (NLM, NCT04855747). REL-1017 will also be evaluated as monotherapy in MDD patients in a randomized, placebo-controlled, phase III trial (RELIANCE-III) with a duration of 28 days (NLM, NCT05081167). However, another phase III trial is dedicated to the open-label evaluation of the long-term safety of REL-1017 as adjunctive treatment of MDD.
and is expected to recruit 600 participants for a monitoring period of 52 weeks (NLM, NCT04855760).

AZD6765 (lanicemine) is a low-trapping NMDA-receptor channel blocker, with an affinity for GluN2A and GluN2B complexes, with antidepressant efficacy demonstrated in three out of four clinical studies (Agbo et al., 2017; Sengupta et al., 2019). Lanicemine has a fast off-rate and is a low-trapping NMDA-receptor antagonist, unlike ketamine and MK-801 properties that lead to a favorable safety profile (Sengupta et al., 2019). This drug also acts over opiate, sigma, and muscarinic receptors (Sengupta et al., 2019). The results of two phase I studies in healthy subjects and two phase II trials in MDD patients were integrated into a pharmacokinetic analysis, and the model developed adequately described lanicemine properties in both clinical and non-clinical samples (Sanacora et al., 2014; Agbo et al., 2017). In both phase II trials, 100 mg lanicemine was efficient in decreasing the MADRS total score, and most of the secondary outcome measurements were up to 3 weeks (Sanacora et al., 2014).

In a randomized, multicenter, parallel-arm, double-blind, placebo-controlled, phase IIb trial, 302 adult patients with MDD and inadequate treatment response received 15 double-blind i.v. infusions of adjunctive lanicemine 50 mg, lanicemine 100 mg, or saline over a 12-week course, in addition to ongoing antidepressants (Sanacora et al., 2017). Lanicemine was generally well-tolerated, but neither dose was superior to placebo in decreasing the severity of the depressive symptoms (Sanacora et al., 2017). Lanicemine was generally well-tolerated, but neither dose was superior to placebo in decreasing the severity of the depressive symptoms (Sanacora et al., 2017).
placebo on two test days, 1 week apart (Zarate et al., 2013). The MADRS score significantly improved, within 80 min, in subjects receiving AZD6765 compared to placebo, but this improvement remained significant only for 110 min (Zarate et al., 2013). The HAMD scores reflected a difference between groups at 80 and 110 min and also on day 2 (Zarate et al., 2013). The response rate was 32% in the AZD6765-treated group versus 15% in placebo-treated patients (Zarate et al., 2013). No difference between groups was reported in the rate of psychotomimetic and dissociative adverse effects (Zarate et al., 2013).

The contradictory results regarding the efficacy of lanicemine in phase II trials raise important questions about the drug dosage, the relevance of the placebo effect, and the potential factors that may influence treatment response in MDD patients.

TAK-653 is an AMPA receptor potentiator with virtual no agonistic activity in animal models (Hara et al., 2021). Both acute and sub-chronic administration of TAK-653 in rats produced significant antidepressant-like effects on the reduction of the submissive behavior model but did not induce a hyper locomotor response, which is a behavioral index associated with psychotomimetic side effects in humans (Hara et al., 2021).

A phase I, randomized, crossover, double-blind, placebo-controlled study enrolled 24 healthy volunteers to evaluate the central nervous system pharmacodynamic activity of TAK-653 in healthy volunteers using transcranial magnetic stimulation (TMS) (O’Donnell et al., 2021). Doses of 0.5 and 6 mg of TAK-653 or placebo were administered, and single-pulse or paired-pulse motor cortex TMS (spTMS and ppTMS) coupled with electromyography as evidence of cortical excitability change under treatment were monitored (O’Donnell et al., 2021). TAK-653 increased the amplitude of motor-evoked potentials in study participants but did not affect resting motor threshold or paired-pulse responses (O’Donnell et al., 2021). Another phase I, randomized study recruited 88 healthy subjects in order to evaluate the safety, tolerability, and pharmacokinetics of escalating single and multiple doses of TAK-653 (NLM, NCT02561156). The overall tolerability of the investigational product was good, with no severe adverse events being reported (NLM, NCT02561156).

A phase II clinical trial assessing the efficacy and safety of TAK-653 in TRD was withdrawn by the sponsor (NLM, NCT03312894).

(2R,6R)-Hydroxynorketamine is a metabolite of ketamine/esketamine, which does not bind to the NMDA receptors and does not cause dissociative effects or abuse potential in mice (Zanos et al., 2016). The antidepressant actions of hydroxynorketamine involve early and sustained AMPA-receptor activation, according to a preclinical model of depression (Zanos et al., 2016). A double-blind, placebo-controlled, phase I, single ascending dose and multiple ascending dose study focusing on the safety, pharmacokinetics, and pharmacodynamics of (2R,6R)-hydroxynorketamine in healthy volunteers is ongoing, with a total of 48 subjects planned to be enrolled (NLM, NCT04711005).

NRX-100/NRX-101 consists of an initial single dose of ketamine (NRX-100) administered intravenously for clinical stabilization, followed by oral D-cycloserine plus lurasidone (NRX-101), and this sequential treatment regimen has as its main indication the control of suicidal ideation/behavior in bipolar depression (Hecking et al., 2021). Ketamine is an NMDA-receptor antagonist, and lurasidone is an atypical antipsychotic with 5HT2A/D2 receptor antagonist properties (Hecking et al., 2021). D-Cycloserine component of the NRX-101 is included in this combination because of its effects on inhibiting NMDA receptors and raising levels of glutamate/glutamine (Glx) in the anterior cingulate cortex (NLM, NCT03396068). Increased Glx has been reported to correlate with clinical improvement following electroconvulsive therapy and following i.v. the administration of ketamine, according to magnetic resonance spectroscopy studies (NLM, NCT03396068).

The efficacy of the sequential administration of NRX-101 has been explored in a randomized, active-comparator, phase II trial, with the main outcome being the BDM (Bipolar Inventory of Symptoms Scale-derived MADRS) score change from baseline to day 42 (NLM, NCT02974010). This trial had four arms: ketamine followed by oral NRX-101, ketamine followed by oral lurasidone, saline solution followed by oral NRX-101, and saline solution followed by oral lurasidone (NLM, NCT02974010). Many 22 adult subjects diagnosed with bipolar depression and suicidal ideation or behavior were randomized in this trial (NLM, NCT02974010). The results (yet unpublished in a peer-reviewed journal) support the superior efficacy of ketamine followed by NRX-101 versus ketamine followed by lurasidone, as reflected by the Bipolar Inventory of Symptoms Scale-derived MADRS (BDM) scores at day 42 (NLM, NCT02974010). No significant difference in the rate of adverse events was observed between NRX-101 and lurasidone-treated groups (NLM, NCT02974010).

NRX-101 is currently undergoing a randomized, active comparator (lurasidone), phase II trial on patients diagnosed with bipolar depression and suicidal ideation, following initial stabilization with ketamine (NLM, NCT02974010). The main outcome of this trial is the improvement of depressive symptoms as measured by MADRS total score, and the expected enrollment is 72 participants (NLM, NCT02974010). Another randomized, active comparator (lurasidone), phase II/III trial focused on the efficacy of NRX-101 in patients diagnosed with moderate bipolar depression and suicidal ideation is expected to begin recruitment, and its primary outcome will be the improvement of depressive symptoms severity measured by MADRS during 6 months (NLM, NCT03395392). A randomized, phase II/III, Glx biomarker validation study is planned to recruit 24 participants diagnosed with bipolar depression who will receive either NRX-101 versus placebo or NRX-101 versus lurasidone (NLM, NCT03402152). In this trial, the main outcome will be the mean change in the Glx area under the curve (AUC) measured after the administration of the investigational product versus the active comparator (NLM, NCT03402152).

The efficacy of NRX-100 (0.5 mg/kg over 40 min) is investigated in an ongoing, randomized, placebo-controlled, phase III trial, in which the primary outcome is the Columbia Suicidality Severity Scale (C-SSRS) score (NLM, NCT03396601). The main objective of this trial is to determine if NRX-100 is superior to placebo infusion in the...
rapid stabilization of patients with severe bipolar depression and active suicidal ideation and behavior, determined after 24 h by the percentage of participants who achieve response (C-SSRS score ≤3) (NLM, NCT03396601). Subjects who respond to NRX-100 will be offered enrollment in a 6-week follow-up study of NRX-101 versus SOC to validate the maintenance effect of ketamine (NLM, NCT03396601).

L-4-Chlorokynurenine (AV-101, 4-Cl-KYN) is an antagonist of the allosteric glycine B (GlyB) coagonist site, and this mechanism of glutamatergic modulation is considered better tolerated and safer than NMDA-receptor antagonism (Wallace et al., 2017). AV-101 is the prodrug of 7-chlorokynurenic acid, one of the most potent GlyB antagonists currently known, which possesses ketamine-like antidepressant properties in animal models of depression and efficacy in animal models of neuropathic pain (Zanos et al., 2015; Wallace et al., 2017). When the behavioral responses in animal models, measured on the 24 h forced swim test, learned helplessness test, and novelty-suppressed feeding test, were evaluated, AV-101 induced rapid, dose-dependent, and persistent antidepressant-like effects following a single dose (Zanos et al., 2015). The antidepressant effects of AV-101 were prevented by pretreatment with glycine or alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonists (Zanos et al., 2015). AV-101 was not associated with the rewarding or psychotomimetic effects of ketamine, and it did not lead to locomotor sensitization or stereotypic behaviors (Zanos et al., 2015).

In a randomized, controlled, double-blind, cross-over trial, the effects of AV-101 in patients with TRD were investigated (N = 19 participants) by the administration of 4-Cl-KYN oral monotherapy (1080 mg/day, 7 days, then 1440 mg/day, 7 days) or placebo (14 days) (Park et al., 2020). The administration of AV-101 was preceded by a period of 2 week drug-free regimen (Park et al., 2020). No treatment effects were detected using linear mixed models, as determined by primary (HAM-D score) or secondary outcome measures (Park et al., 2020). No difference between groups for any peripheral or central biological indices or adverse effects was reported (Park et al., 2020). These negative results raise doubts related to the capacity of AV-101 to penetrate the brain and engage the NMDA receptors and the kynurenine pathway effectively (Murphy et al., 2021). To verify this aspect, another randomized, double-blind, placebo-controlled, crossover, phase I study (N = 10 healthy volunteers) explored the dose-related effects of AV-101 (720 and 1440 mg) on the engagement of the NMDA receptors (Murphy et al., 2021). The results showed that only the high dose (1440 mg) of AV-101 in humans succeeded in engaging brain targets in humans, suggesting the necessity of testing these doses in depression (Murphy et al., 2021).

Rapastinel (GLYX-13) is an NMDA-receptor modulator with glycine-site partial agonist properties, which possesses cognitive enhancement properties and rapid and long-lasting antidepressant activity in both animal models and humans (Burgdorf et al., 2015a). In clinical trials, rapastinel produced marked antidepressant effects that last for at least 1 week after a single dose (Moskal et al., 2014; Burgdorf et al., 2015b). Animal models of depression support the existence of a hippocampal long-term potentiation effect of rapastinel that persisted up to 2 weeks after a single dose (2 mg/kg i.v.), supposedly via triggering NMDA-receptor-dependent processes and increasing the mature spine density in the hippocampus and medial prefrontal cortex in rats (Burgdorf et al., 2015b).

Of the three trials identified in the clinicaltrials.gov archive, which refers to the effects of rapastinel in MDD patients, only two have results. The first proof-of-concept trial was double-blind, placebo-controlled, randomized, phase II, single i.v. GLYX-13 (1, 5, 10, or 30 mg/kg) and enrolled 116 participants with MDD who had not benefited from at least one monoaminergic antidepressant for their current episode (Preskorn et al., 2015). GLYX-13, administered at a 5 or 10 mg/kg i.v. dose reduced depressive symptoms (measured by HAMD-17) on days 1–7 (Preskorn et al., 2015). The antidepressant effect had its onset within 2 h and persisted for 7 days on average (Preskorn et al., 2015). No psychotomimetic or other significant adverse events were reported (Preskorn et al., 2015).

The second trial, with undisclosed results, included 369 participants with MDD and inadequate/partial response to antidepressants, and it had a double-blind, placebo-controlled, randomized withdrawal design (NLM, NCT01684163). A phase II, open-label extension trial investigated the safety of long-term repeat exposure to GLYX-13 in subjects who participated in the previously mentioned trial (NLM, NCT02192099; NLM, NCT01684163). In the extension, rapastinel (250/450 mg i.v.) was administered to 61 participants with completed eight or more weeks of treatment in the previous study and were willing to continue treatment (NLM, NCT02192099). Participants who were originally assigned to 5 mg/kg received 225 mg rapastinel, and those assigned to 10 mg/kg in the first trial received 450 mg active drug (NLM, NCT02192099). Unpublished results posted on the clinicaltrials.gov site show a high rate of severe adverse events (SAE) (23%) and adverse events (98%) collected during 48 months (NLM, NCT02192099). Therefore, this study was terminated by the sponsor in 32 cases, and 11 participants withdrew.

Apimostinel (NRX-1074) is a compound with NMDA-receptor modulating properties, more specifically, a functional antagonist at the GlyB site of the NMDA receptors (Wilkinson and Sanacora, 2019). This product was investigated in phase I trials as i.v. formulation and an orally bioavailable drug candidate (NLM, NCT02366364; NLM, NCT01856556). A phase I trial investigated the safety and tolerability of multiple oral ascending doses of NRX-1074 (375, 500, and 750 mg) in 15 healthy volunteers, but the results have not yet been released (NLM, NCT02366364). The phase I trial investigating i.v. and oral formulae also has undisclosed results (NLM, NCT01856556).

NRX-1074 led to statistically significant improvement in MDD 24 h after intravenous administration (1, 5, or 10 mg) in a randomized, double-blind, placebo-controlled phase II study (Brooks, 2015). The improvement reported after one dose of NRX-1074 infusion had an effect size (0.88), more than double the average effect size typically seen with most antidepressants after 4–6 weeks of a repeated dose, according to the company release note (Brooks, 2015). This trial recruited 140 patients with
MDD, and the primary outcome measure was HAMD-17 (Brooks, 2015). It was also observed that 72% of the patients receiving the highest of the three tested doses demonstrated a clinically meaningful response at 24 h versus 39% in the placebo group (Brooks, 2015).

The antidepressant effects of ketamine are supported by randomized clinical trials, with a fast onset of action, high response rates in TRD, and efficacy against suicidality (Lacerda, 2020). While intranasal esketamine was approved by FDA in 2019 for TRD, when added to a traditional oral antidepressant, the racemic mixture of ketamine is currently investigated for MDD (Bahr et al., 2019). Ketamine/esketamine are non-competitive NMDA-glutamate receptor antagonists, with a higher affinity for these receptors in the case of S-ketamine enantiomer (Bahr et al., 2019). The mechanisms of action underlying their positive effects on MDD are unclear, but they probably involve improvement of brain plasticity via stimulation of BDNF (brain-derived neurotrophic factor) production and activation of the mammalian target of rapamycin (mTOR) (Sattar et al., 2018; Bahr et al., 2019). Ketamine and esketamine actions over the mTOR pathway are responsible for additional stimulation of BDNF, thus increasing brain plasticity through dendritic growth and improving synaptic transmission (Ignacio et al., 2016; Bahr et al., 2019).

A meta-analysis (n = 14 clinical trials) showed that a single infusion of (R,S)-ketamine (0.5 mg/kg, 40 min) induces a response rate of 50%–70% in TRD (Kishimoto et al., 2016). According to a meta-analysis that evaluated the efficacy of ketamine for the treatment of MDD, the treatment effects may last up to 6 weeks after drug administration (Conley et al., 2021). Another meta-analysis that compared racemic ketamine and esketamine (n = 24 trials, N = 1877 participants) used as primary outcomes the response and remission from depression, change in depression severity, suicidality, retention in treatment, drop-out rate, and drop-outs due to adverse events, concluding that ketamine was associated with greater overall response and remission rates, as well as lower dropouts (Bahji et al., 2021).

A randomized, phase III trial evaluated the effects of i.v. ketamine (0.1, 0.25, or 0.5 mg/kg) versus midazolam (0.03 mg/kg) in 33 military veterans with late-life TRD (NLM, NCT02556606). The rate of response (50% reduction on MADRS total score) at day 7 was 72.7% for 0.5 mg/kg ketamine i.v. versus 46.2% for midazolam (active placebo) and 87.5% versus 66.7% at day 28 (NLM, NCT02556606).

Another interesting study evaluated the efficacy of low-dose ketamine administered during cesarean delivery as a method to decrease the incidence of postpartum depression in parturients with prenatal depression (NLM, NCT03336541). This phase IV trial was completed, but its results are not available.

SLS-002 is the racemic mixture of ketamine with intranasal administration, currently undergoing phase II clinical trials (NLM, NCT04669665). In a randomized, double-blind, crossover study, 20 TRD participants received intranasal ketamine hydrochloride (50 mg) or saline solution and were monitored for 7 days (Lapidus et al., 2014). Patients treated with ketamine had significant improvements in their depressive symptoms 24 h after drug administration, and the overall tolerability was good, with minimal adverse effects (Lapidus et al., 2014).

A phase II, randomized, initial open-label sequence and a double-blind, randomized, placebo-controlled second sequence will evaluate the efficacy, safety, and tolerability of SLS-002 in addition to SOC on symptoms of MDD and suicidality, in participants at imminent risk for suicide as determined by change in MADRS total score at 24 h after the first dose (NLM, NCT04669665). In the first part of the study, 17 patients were enrolled, and SLS-002 demonstrated a rapid onset of action from the first dose through the last visit, with the mean MADRS scores meeting the remission criteria on day 6 (PRNewswire, 2021a).

R-Ketamine (PCN-101), or arketamine, has been associated with a longer-lasting and more potent antidepressant effect than ketamine and esketamine in animal studies (Zhang et al., 2014). Because it proved to have weaker hypnotic and analgesic actions than the racemate and esketamine in humans, arketamine did not become commercially available for anesthesiology use (Leal et al., 2021). Unlike S-ketamine, arketamine can elicit a sustained antidepressant effect in mice, which appears to be mediated by increased BDNF-TrkB signaling and synaptogenesis in the prefrontal cortex, dentate gyrus, and CA3 hippocampal region (Yang et al., 2015). Arketamine was not associated with abuse or psychotomimetic activity (Yang et al., 2015).

In an open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg), and the MADRS score at 24 h after administration was defined as the primary outcome (Leal et al., 2021). The mean MADRS score changed significantly, with 20.3 points in 24 h, and no clear dissociative symptoms were reported (Leal et al., 2021). A phase I, two-stage, single-center, randomized, placebo-controlled, double-blind study evaluated first the safety, tolerability, and pharmacokinetics of single PCN-101 ascending doses in 58 healthy adult volunteers, administered via intravenous infusion (PRNewswire, 2021b). PCN-101 was safe and well-tolerated at all doses up to 150 mg, and no SAE were reported, according to the manufacturer’s press release (PRNewswire, 2021b). In the second stage of the study, the relative safety and tolerability of PCN-101 were compared to that of S-ketamine, and the results showed that substantially higher doses of PCN-101 are required to obtain similar perceptual changes with S-ketamine (PRNewswire, 2021b).

N-Methylglycine (sarcosine) inhibits glycine transporter-I and thus potentiates the NMDA function, improving depression-like behavior in rodent models and depression in humans (Chen et al., 2017). A single dose of sarcosine produced an antidepressant-like effect with rapid concomitant increases in the mTOR signaling pathway activation and enhancement of the AMPA receptor membrane insertion in rats (Chen et al., 2017). Long-term administration of sarcosine had favorable effects in
rats exposed to chronic unpredictable stress but not in stress-naive rats (Chen et al., 2017).

In a complex study, which explored the efficacy of sarcosine in animal models and depressed patients, the results were favorable: 1) sarcosine decreased immobility in the forced swim test and tail suspension test, reduced the latency to feed in the novelty-suppressed feeding test, and reversed behavioral deficits caused by chronic unpredictable stress test in an animal model of depression; 2) in MDD patients (N = 40), sarcosine (500–1500 mg/day sarcosine) improved significantly HAMD, Clinical Global Impression (CGI), and GAF scores more than citalopram (20–60 mg/day) treatment, and it was associated with a higher probability of symptom remission, quicker response, and less risk for drop out (Huang et al., 2013; NLM, NCT04975100).

A phase IV clinical trial designed to evaluate the efficacy of sarcosine as an add-on to currently administered antidepressants in patients with MDD is ongoing and is estimated to recruit 60 adult participants who will be randomized on sarcosine + SSRI or placebo + SSRI (NLM, NCT04975100). The primary outcome measure is the change in depressive symptoms severity from baseline, assessed with MADRS, during 8 weeks (NLM, NCT04975100).

D-Cycloserine is an antibiotic that also possesses partial agonistic properties at the NMDA-receptor-associated modulatory glycine site, and at dosages ≥100 mg/day, it acts as a functional NMDA-receptor antagonist with antidepressant effects (Heresco-Levy et al., 2006). In a double-blind, placebo-controlled 6-week crossover trial, 22 TRD patients received 250 mg/day of D-cycloserine added to their ongoing antidepressant (Heresco-Levy et al., 2006). D-Cycloserine induced symptoms reduction and was well tolerated, but the efficacy did not reach statistically significant levels in patients with D-cycloserine versus placebo adjuvant treatment (Heresco-Levy et al., 2006). In another double-blind, placebo-controlled, 6-week, parallel-group trial, 26 TRD patients received a gradually titrated high dose (1000 mg/day) of D-cycloserine added to their current antidepressant (Heresco-Levy et al., 2013). D-Cycloserine was well tolerated, had no psychotomimetic effects, and improved significantly depressive symptoms versus placebo, as measured by HAMD and BDI scores (Heresco-Levy et al., 2013). Also, pretreatment glycine serum was considered a relevant variable that interacted with the treatment outcome (Heresco-Levy et al., 2013). This second trial suggested that the antagonistic properties of D-cycloserine begin at a higher dose than expected in the first trial, probably above the level of 500 mg/day.

In another trial, 32 patients with TRD (17 with MDD and 15 with bipolar depression) who responded to ketamine infusion with an average 9.47 ± 4.11 HAMD score at baseline were randomly divided into 6-week D-cycloserine treatment versus placebo (Chen et al., 2019). During the 6-week treatment, the total HAMD scores did not differ between the two groups, but a potential effect of D-cycloserine over suicide ideation/behavior was identified by mixed model analysis throughout the follow-up period (Chen et al., 2019).

The administration of D-cycloserine as a pre-treatment before computer-based cognitive-behavioral therapy (CBT) sessions for depression to assess the impact of this approach on therapeutic learning has been explored in a randomized, phase II trial of 36 participants (NLM, NCT02376257). D-Cycloserine (250 mg/day) was compared in this trial with modafinil (100 mg/day) and placebo, and the primary outcome measures were the recall of CBT content, the delayed recall of emotional story items, and the delayed recall of logical memory after 2 and 3 weeks (NLM, NCT02376257). The results of this trial have not yet been published in a peer-review journal.

Dextromethorphan has competitive, low-affinity NMDA-receptor antagonist properties and σ-1 receptor-agonist and nicotinic antagonist effects (Nguyen et al., 2016). Dextromethorphan inhibits the serotonin transporter and the norepinephrine transporter to a lesser extent (Nguyen et al., 2016). It also inhibits voltage-gated calcium channels (Nguyen et al., 2016). According to a review of the clinical and preclinical studies referring to the efficacy and tolerability of dextromethorphan, this agent is well tolerated and exerts clinically significant antidepressant effects, especially in adults with bipolar depression (Majeed et al., 2021). In a randomized, double-blind, 12-week clinical trial, 309 patients with bipolar disorder received either valproic acid and low-dose (30 or 60 mg/day) dextromethorphan or valproic acid plus placebo (Chen et al., 2014). Before treatment, patients with bipolar disorder had significantly higher plasma cytokine and lower plasma BDNF levels than healthy controls, and after treatment, HAMD and Young Mania Rating Scale (YMRS) scores in each treatment group showed significant improvement (Chen et al., 2014). Plasma cytokine levels declined in all groups, and changes in BDNF levels were significantly greater in the valproic acid + dextromethorphan 60 mg/day group than in the valproic acid + placebo group (Chen et al., 2014).

Nitrous oxide has a largely unknown mechanism of action, but it is considered a non-competitive inhibitor of NMDA-glutamate receptors (Kalmoe et al., 2020). Its main clinical use is inhalational general anesthesia and analgesia for short procedures, but it is also used recreationally by adolescents and young adults (Kalmoe et al., 2020). The euphoria-inducing effects of nitrous oxide have been hypothesized to have clinical benefits in patients with MDD (Kalmoe et al., 2020). In a proof-of-concept, placebo-controlled crossover trial, 20 patients with TRD were randomized to 1 h inhalation of 50% nitrous oxide/50% oxygen or 50% nitrogen/50% oxygen (the last one being equivalent to placebo) (Nagele et al., 2015). Depressive symptoms improved significantly at 2 and 24 h after nitrous oxide administration versus placebo (according to HAMD-21 scores) (Nagele et al., 2015). Treatment response was observed in four patients (20%), and three patients had a full remission after nitrous oxide versus one patient (5%) and none after placebo (Nagele et al., 2015). No SAE occurred, and all adverse events were brief and of mild-to-moderate severity (Nagele et al., 2015). Another phase II, randomized, double-blind trial that evaluated the efficacy of inhaled nitrous oxide for TRD investigated the impact of nitrous oxide 25% or 50% versus placebo over HAMD-21 scores at 2 and 24 h after inhalation in 34 patients, but results have not been disclosed (NLM, NCT03283670).
**Riluzole** is a neuroprotective agent which inhibits the voltage-dependent sodium channels on glutamatergic nerve terminals and activates AMPA/kainate receptors, but it may induce a noncompetitive blockade of NMDA receptors (Doble, 1996; Zarate et al., 2004).

In an open-label trial, 19 patients diagnosed with treatment-resistant depression received riluzole 168.8 mg/day (mean dose) for 6 weeks (Zarate et al., 2004). Significant improvement in MADRS scores occurred in weeks 3–6, in trial completers, and CGI-S and HAMA also improved significantly during weeks 3–6 (Zarate et al., 2004). The response rate for completers at week 6 was 46%, and the remission rate was 31% (Zarate et al., 2004). The most common adverse events during the trial were headache (58%), gastrointestinal distress (43%), tension, or inner unrest (26%) (Zarate et al., 2004).

In an open-label trial, 100–200 mg riluzole was administered for 6 weeks to 14 patients with bipolar depression, and it led to a significant reduction of HAMD scores, while the glutamate/glutamate (Gln/Glu) ratios increased significantly by day 2 of the treatment (Brennan et al., 2010). N-Acetyl aspartate (NAA) levels increased in NAA from baseline to week 6 (Brennan et al., 2010). Therefore, riluzole seems to rapidly increase the Gln/Glu ratios, suggesting increased glutamate-glutamine cycling, which may lead to enhanced neuronal plasticity and reduced depressive symptoms (Brennan et al., 2010).

Riluzole was added to ongoing medication for 6 weeks, followed by an optional 6-week continuation phase in 10 patients diagnosed with treatment-resistant depression (Sanacora et al., 2007). HAMD and HAMA scores declined significantly following the initiation of riluzole augmentation treatment, and the effect of riluzole became significant at the end of the first week of the trial and persisted for the 12-week duration of monitoring (Sanacora et al., 2007).

A phase II, randomized, double-blind, placebo-controlled, adjunctive trial on treatment-resistant MDD enrolled 104 participants who received 1) 100 mg riluzole added to ongoing SSRI/SNRI for 8 weeks, 2) riluzole/placebo added to SSRI/SNRI for 4 weeks and placebo added to the same agents for another 4 weeks, or 3) placebo added to SSRI/SNRI for 8 weeks (NLM, NCT01204918). The main outcome measures were the change in MADRS scores after 4 and 8 weeks (NLM, NCT01204918). The final results of this trial were not published in a journal, but the rough data available on the clinicaltrials.gov site did not support a large difference between groups, while the response rate at week 8 (secondary outcome) was higher for placebo than for any of the active groups (NLM, NCT01204918).

Another randomized, double-blind, phase II trial evaluated the efficacy of riluzole (50 mg b.i.d) versus placebo as an add-on to sertraline (100 mg/day) in 21 outpatients diagnosed with MDD during 8 weeks, and the primary outcome measures were the mean change in HAMD scores from baseline to endpoint and the number of patients with antidepressant response or remission at week 8 (NLM, NCT01703039). This study was prematurely terminated due to administrative reasons.

Another 6-week, single-arm, single-blind phase II study enrolled 31 patients with MDD without psychotic features and evaluated the efficacy of riluzole (NLM, NCT00026052). The study was completed, but no results were posted or published.

A randomized, placebo-controlled, double-blind, continuation-phase IV study evaluated the safety and effectiveness of ketamine and riluzole in patients with treatment-resistant MDD (Mathew et al., 2010). A total of 26 medication-free patients received open-label i.v. ketamine (0.5 mg/kg over 40 min), and before infusion, they were randomized to lamotrigine (300 mg) or placebo (Mathew et al., 2010). The response rate was 65% (17 patients), according to the MADRS scores at 24 h following ketamine, while lamotrigine failed to attenuate the mild, transient side effects associated with ketamine and did not enhance its antidepressant effects (Mathew et al., 2010). After 72 h of infusion, the response was obtained by 14 patients (54%), and they were randomized to continue with riluzole (100–200 mg/day) or placebo (Mathew et al., 2010). An interim analysis did not find any significant differences between riluzole and placebo regarding the main outcome (time-to-relapse), with 80% of patients relapsing on riluzole versus 50% on placebo (Mathew et al., 2010). Therefore, the trial was discontinued for futility.

A randomized, placebo-controlled, double-blind, phase II trial evaluated the efficacy and safety of riluzole (50–200 mg/day) in 94 participants diagnosed with bipolar depression for 8 weeks, and the main outcome measure was the mean change in MADRS score (NLM, NCT00376220). The results were posted on clinicaltrials.gov and did not support the superior efficacy of riluzole versus placebo (NLM, NCT00376220).

Another 8-week, open-label study of riluzole (50–200 mg/day) in combination with lithium recruited 14 acutely depressed bipolar patients (MADRS score ≥20) who first followed 4 weeks of lithium treatment (Zarate et al., 2013). The linear mixed model for total MADRS score showed a significant treatment effect at week 8, without cases of switch into hypomania or mania (Zarate et al., 2013).

An 8-week, double-blind, placebo-controlled, phase II trial evaluated the efficacy and safety of riluzole (50–200 mg/day) in 19 participants diagnosed with bipolar depression, but the study was terminated due to the superior efficacy of placebo in an interim analysis (NLM, NCT00054704).

**Memantine** is classified as an NMDA-receptor-open channel blocker because it can enter these channels and block current flow only after they are opened (Johnson and Kotermanski, 2006). A double-blind, placebo-controlled trial enrolled 32 patients diagnosed with MDD, randomized on memantine (5–20 mg/day) or placebo for 8 weeks (Zarate et al., 2006). The results of this trial did not support the efficacy of memantine based on the linear mixed models for total MADRS scores (Zarate et al., 2006). Another randomized, double-blind, placebo-controlled trial evaluated the efficacy of memantine (5–20 mg/day) as an add-on to antidepressant treatment in 31 participants with partial or non-responsive MDD for 8 weeks (Smith et al., 2013). No significant change in MADRS scores was detected in patients who received memantine versus those on placebo, either over the entire study or at study completion (Smith et al., 2013). A minimal-to-small effect size was observed, favoring placebo (d = 0.19) (Smith et al., 2013). No statistical differences were
observed between groups on secondary efficacy outcomes or safety outcomes (Smith et al., 2013).

A phase IV, randomized, placebo-controlled trial investigated the efficacy and safety of memantine (5–20 mg) augmentation administered for 8 weeks in 29 adult patients diagnosed with bipolar depression and incomplete response to lamotrigine (NLM, NCT0035578). The primary outcome was the change in HAMD-17 from baseline to week 8, and the posted results on clinicaltrials.gov show a decrease of 9 versus 7 points in patients treated with memantine versus placebo (NLM, NCT0035578). The most frequently reported adverse events in the memantine group were somnolence, indigestion, diarrhea, headache, and coughing (NLM, NCT0035578).

A double-blind, randomized, phase III trial evaluating the efficacy and safety of memantine (5–20 mg/day) included three phases: during the first stage, adult outpatients with MDD without psychiatric features (N = 112) have tapered off all psychiatric medications over 2 weeks (washout period); in the second phase, participants were randomized on memantine or placebo three times a day for 8 weeks; and participants who responded well to the treatment entered phase III, a 16-week continuation period of either memantine or placebo (NLM, NCT0040261). No results of this trial have been released.

However, another single-site, double-blind, placebo-controlled, parallel-group, phase IV trial enrolled 31 participants diagnosed with MDD and non-response or incomplete response to antidepressants were randomized on either memantine (5–20 mg/day) or placebo as an add-on for 8 weeks (NLM, NCT00344682). The main outcome was the change in MADRS scores at week 8, and the results posted on clinicaltrials.gov did not support a significant difference between groups (7.13 vs. 7.25 points in memantine vs. placebo) (NLM, NCT00344682). The rate of serious adverse events was similar in the two groups (20 vs. 18.75% in memantine vs. placebo) (NLM, NCT00344682).

The blockade of metabotropic glutamate 2/3 (mGlu2/3) receptors is considered a potentially interesting approach in the treatment of MDD, based on several preclinical studies (Sanacora et al., 2008; Watanabe et al., 2021). TP0473292 (TS-161) is the prodrug of a novel mGlu2 receptor antagonist, investigated in trials for MDD treatment (Watanabe et al., 2021). In a first-in-human, randomized, double-blind, single ascending dose (15–400 mg) and 10-day-multiple-ascending dose (50–150 mg), phase I trial on healthy subjects (N = 70), the pharmacokinetic profile of TS-101 was described (Watanabe et al., 2021). The prodrug was extensively converted into its active metabolite, and plasma exposure to this metabolite increased with the dose administered (Watanabe et al., 2021). The investigational product penetrated the brain–blood barrier, and the most frequently reported adverse events were nausea, vomiting, and dizziness, with an exposure-related incidence (Watanabe et al., 2021). An ongoing, placebo-controlled, phase II study is dedicated to the evaluation of TS-161 efficacy in TRD, with the main outcome being the change from baseline to day 21 on MADRS total scores and an estimated enrollment of 25 participants (NLM, NCT04821271).

On the contrary, decoglurant (RO4995819), a mGlu2/3 receptor negative allosteric modulator, failed in a phase II trial to exert any antidepressant or procognitive effects (Umbricht et al., 2020). During this 6-week, double-blind, multicenter, randomized trial, 357 participants diagnosed with MDD who did not respond to two adequate trials of an SSRI/SNRI received decoglurant 5 mg (N = 101), 15 mg (N = 102), or 30 mg (N = 55) daily, or placebo (N = 99) although their adherence was confirmed through positive drug levels (Umbricht et al., 2020). At week 6, no significant differences were observed between any active treatment arms and placebo in decreasing MADRS scores, in response, or in remission rates (Umbricht et al., 2020). No effects of decoglurant were observed on Cambridge Neuropsychological Test Automated Battery (CANTAB)—cognitive accuracy and cognitive speed composite scores (Umbricht et al., 2020). High placebo response was observed, which may impair the ability of this trial to detect an efficacy signal. Another phase II trial that was intended to evaluate the efficacy of decoglurant versus placebo as adjunctive therapy in patients with MDD and inadequate response to their ongoing antidepressant was withdrawn by the sponsor (NLM, NCT01733654).

Metabotropic glutamate type 5 (mGlu5) receptors are ubiquitously expressed throughout the brain, and their dysfunction is involved in the pathogenesis of several diseases, for example, Alzheimer’s disease, Parkinson’s disease, and MDD (NLM, NCT01145755). Despite the success of the negative allosteric mGlu5 receptor modulators in preclinical studies, no such agent has been associated with favorable results in clinical trials with MDD patients (NLM, NCT01145755). Basinglurant (RG-7090, RO-4917523) is a potent and selective mGlu5 receptor negative allosteric modulator with good oral availability and a long half-life, which allows for once-daily administration (Lindemann et al., 2015; Quiroz et al., 2016). It has antidepressant properties and anxiolytic-like and antinoceptive effects (Lindemann et al., 2015). In a phase Ib, multicenter, double-blind, randomized clinical trial, basinglurant MR (0.5 or 1.5 mg) was compared with placebo in 333 adult patients with MDD, as adjunctive to ongoing antidepressant medication (an SSRI or SNRI agent), for 6 weeks (Quiroz et al., 2016). No difference was observed in the primary outcome, MADRS change from baseline to the endpoint, between basinglurant MR and placebo (Quiroz et al., 2016). Secondary endpoints were modified by adjunctive basinglurant MR 1.5 mg daily, especially in patient-rated measures (Quiroz et al., 2016). The most frequently reported adverse event was dizziness, but it was of mild intensity and transient (Quiroz et al., 2016). Another phase I, single-center, randomized, multiple-ascending dose trial, evaluated the safety of basinglurant versus placebo (N = 56 participants with MDD or healthy subjects) (NLM, NCT02433093). No results of this trial were posted as of February 2022.

AZD2066 is a mGlu5 receptor antagonist that was assessed in a phase IIa, multicenter, randomized, double-blind, double-dummy, active ( Duloxetine), placebo-controlled, and parallel-group study on 131 patients diagnosed with MDD, and the results (posted on clinicaltrials.gov) were negative (MADRS
et al., 2019).

mood, for example, the medial prefrontal cortex (Sengupta et al., 2019). Suppressed mTORC1 signaling has been suggested as a possible pathogenic mechanism in MDD, and amino acids (Sengupta et al., 2019). The inhibition of mTORC1 by sestrins 1 and 2 can be reversed by the in vivo signaling, both in vivo and in vitro, orally available, and can transiently activate mTORC1 in several peripheral tissues and the brain (Sengupta et al., 2019). The impact of NV-5138 on synaptic function and BDNF signaling is similar to ketamine, suggesting a shared mTORC1 signaling-mediated mechanism for their antidepressant effect (Kato et al., 2019). A single dose of NV-5138 produced a rapid and long-lasting antidepressant effect and rapidly reversed anhedonia caused by chronic stress exposure in animal models of depression (Kato et al., 2019). The antidepressant action of NV-5138 required BDNF release, as the behavioral responses were blocked by infusion of BDNF-neutralizing antibodies into the medial prefrontal cortex (Kato et al., 2019).

NV-5138 is a novel small molecule activator of mTORC1 signaling, both in vivo and in vitro, orally available, and can transiently activate mTORC1 in several peripheral tissues and the brain (Sengupta et al., 2019). The impact of NV-5138 on synaptic function and BDNF signaling is similar to ketamine, suggesting a shared mTORC1 signaling-mediated mechanism for their antidepressant effect (Kato et al., 2019). A single dose of NV-5138 produced a rapid and long-lasting antidepressant effect and rapidly reversed anhedonia caused by chronic stress exposure in animal models of depression (Kato et al., 2019). The antidepressant action of NV-5138 required BDNF release, as the behavioral responses were blocked by infusion of BDNF-neutralizing antibodies into the medial prefrontal cortex (Kato et al., 2019).

A randomized, placebo-controlled, phase I trial explored the effects of a single ascending dosage level of NV-5138 in healthy volunteers and a single dose of NV-5138 in subjects with TRD, but no results of this trial have yet been disclosed (NLM, NCT03606395).

Another placebo-controlled, randomized, phase II trial is planned to evaluate the efficacy and tolerability of NV-5138 in adults with TRD (estimated enrollment: 40 participants), with a monitoring period of 5 weeks, and MADRS change to baseline as the primary outcome measure (NLM, NCT05066672).

In conclusion, glutamate modulators are a promising class of antidepressant agents, although several molecules have failed in different stages of clinical development. The recent FDA approval of intranasal esketamine as an adjunctive agent for TRD is an argument in favor of glutamatergic neurotransmission importance in the pathophysiology of mood disorders.

**Sestrin Modulators**

Sestrins are small, stress-induced proteins with multiple roles; for example, they are involved in oxidative stress, DNA damage response, cell growth, metabolic homeostasis, and mTORC1 signaling (Sengupta et al., 2019). The inhibition of mTORC1 by sestrins 1 and 2 can be reversed by the influx of sufficient levels of amino acids, whereas sestrin 3 cannot be regulated by amino acids (Sengupta et al., 2019). Suppressed mTORC1 signaling has been suggested as a possible pathogenic mechanism in MDD, and NMDA receptor modulators such as ketamine are dependent upon the mTORC1 activation in brain areas responsible for mood, for example, the medial prefrontal cortex (Sengupta et al., 2019).

**Table 2**

| Authors | Methodology | Results | Clinical trial phase, trial identifier (if available) |
|---------|-------------|---------|-----------------------------------------------------|
| NLM, (2019g) | NV-5138 vs. placebo, SAD, DBRCT, N1 = 48 (estimated) healthy volunteers and N2 = 40 treatment-resistant MDD, 9 days | The primary outcome was the incidence of treatment-related AE. The results of this trial have not yet been disclosed | Phase I, NCT03606395 |
| NLM, (2021h) | NV-5138 vs. placebo, DBRCT, N = 40 (estimated), TRD patients, 5 weeks | The primary outcome measure was the efficacy measured by MADRS total score. This trial is ongoing | Phase II, NCT05066672 |

AE, adverse events; DBRCT, double-blind, randomized controlled trial; MADRS, Montgomery-Asberg Depression Rating Scale; MDD, major depressive disorder; SAD, single ascending dose; TRD, treatment-resistant MDD.

**Combinations of Pharmacological Agents**

The combination of dextromethorphan and bupropion (AXS-05) is currently explored as an orally administered therapy for patients with MDD, based on the pharmacodynamic properties of an uncompetitive NMDA-glutamate antagonist, σ1 agonist, and nonselective serotonin reuptake inhibitor (dextromethorphan), and a selective norepinephrine/dopamine reuptake inhibitor with nicotinic acetylcholine receptor antagonist properties (bupropion) (Sakurai et al., 2022). Beside its antidepressant properties, bupropion is credited with the protection of dextromethorphan from rapid metabolization via CYP450 2D6 because of this antidepressant potent inhibition of these hepatic isoenzymes (Sakurai et al., 2022).

In a randomized, double-blind, active-controlled, multicenter phase II trial (ASCEND), 80 patients diagnosed with moderate-to-severe MDD were treated for 6 weeks with AXS-05 (45 mg dextromethorphan/105 mg bupropion twice daily) or bupropion (105 mg twice daily) (Axsome Therapeutics, 2019). Change in MADRS score was the primary outcome, and the rate of remission and response was superior for the AXS-05 group at the end-point, with early separation from the bupropion-treated group (Axsome Therapeutics, 2019). The pharmacological combination was safe and well-tolerated, with similar rates of adverse events in the AXS-05 and bupropion arms (Axsome Therapeutics, 2019). In the AXS-05 group, the most frequent adverse events were nausea, dizziness, dry mouth, decreased appetite, and anxiety (Axsome Therapeutics, 2019). No psychotomimetic effects, weight gain, or increased sexual dysfunction were reported in the AXS-05 group (Axsome Therapeutics, 2019).

Another phase II, randomized, double-blind, placebo-controlled, relapse prevention, multicenter trial (MERIT) explored the efficacy of AXS-05 in patients with TRD (N = 44 participants, who presented ongoing symptoms of depression despite receiving treatment with two or more prior antidepressants during the current major depressive episode) (Axsome Therapeutics, 2021). Patients who achieved stable
remission under AXS-05 in a previous trial (MADRS scores ≤ 12 at two or more consecutive visits, separated by at least 4 weeks) were randomized to continue the same treatment or to discontinue it and switch to placebo (Axsome Therapeutics, 2021). AXS-05 met the primary endpoint by significantly delaying the time to relapse of depressive symptoms compared to placebo, with no relapse over ≥6 months (Axsome Therapeutics, 2021). Also, AXS-05 met the key secondary endpoint of relapse prevention, according to the relapse rates during the double-blind period (Axsome Therapeutics, 2021).

In a phase III randomized, double-blind, placebo-controlled, multicenter trial (GEMINI), 327 adult patients diagnosed with moderate-to-severe MDD were randomized to treatment with either AXS-05 or placebo once daily for the first 3 days and twice daily thereafter for a total of 6 weeks (Axsome Therapeutics, 2020). AXS-05 demonstrated a significant reduction in patient-reported depressive symptoms, evaluated by QIDS-SR-16 and CGI-I (Patient Global Impression of Improvement), compared to placebo at week 6 (Axsome Therapeutics, 2020). The response on QIDS-SR-16 total score (at least 50% improvement) was significantly greater for AXS-05 starting from week 1 and at every time point thereafter, with 53.4% of patients achieving response compared to 33% of placebo patients at week 6 (Axsome Therapeutics, 2020). On the CGI-I, AXS-05 demonstrated efficacy versus placebo, with 47.2% of patients achieving the level of “very much” or “much” improvement versus 31.3% of placebo patients at week 6 (Axsome Therapeutics, 2020). The evolution of symptoms measured with clinician-rated scales (i.e., MADRS and CGI-I) supported the favorable results observed on self-reported scales, the difference from placebo being consistent at week 6 (Axsome Therapeutics, 2020). The most commonly reported adverse events associated with AXS-05 were dizziness, nausea, headache, diarrhea, somnolence, and dry mouth (Axsome Therapeutics, 2020).

Another phase III, randomized, double-blind, active-controlled, multicenter trial (STRIDE-1) evaluated the efficacy of AXS-05 in TRD (N = 312 adult participants who had failed two or three prior treatments) but did not show a statistically significant difference between the investigational product (45 mg dextromethorphan/105 mg bupropion, twice daily) and active control (150 mg bupropion, twice daily) after 6 weeks, according to MADRS total score (Biospace, 2020). The secondary outcomes favored, however, AXS-05 versus active control, with significantly higher rates of remission from depression (defined by QIDS-SR-16 ≤ 5) at week 1 and at every time point thereafter (Biospace, 2020). Also, AXS-05 improved cognitive function (monitored by the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire, CPFQ) and reduced anxiety symptoms (Hamilton Anxiety Rating Scale, HAM-A) (Biospace, 2020).

The fixed-dose combination of dextromethorphan hydrobromide and quinidine (DXMQ) was created based on the CYP450 2D6 enzyme inhibition induced by quinidine and the previously mentioned pharmacodynamic properties of dextromethorphan, which recommend this combination as a potential antidepressant therapy (Murrell et al., 2017; Majeed et al., 2021). DXMQ was approved by FDA in 2010 for the treatment of the pseudobulbar affect (Murrough et al., 2017). In an open-label, phase IIa clinical trial examining the efficacy and tolerability of orally administered DXMQ (45 mg/10 mg every 12 h) in 20 patients with TRD during 10 weeks, the MADRS score (primary outcome) significantly decreased from baseline to endpoint (Murrough et al., 2017). The QIDS-SR score also decreased significantly during the DXMQ treatment, and the response and remission rates in the intent-to-treat sample were 45% and 35%, respectively (Murrough et al., 2017).

A retrospective chart review included depressed patients (N = 77) diagnosed with treatment-resistant bipolar disorder type II or NOS, who received treatment with DXMQ 20 mg/10 mg twice daily in addition to their current treatment (Kelly and Lieberman, 2014). On day 90, the CGI-I score was 1.66, and some patients improved their clinical status within 1–2 days after the beginning of DXMQ administration (Kelly and Lieberman, 2014). A significant number of patients (N = 19) discontinued treatment due to adverse events, mainly nausea (Kelly and Lieberman, 2014).

Deudextromethorphan/quinidine (AVP-786) combines d6-dextromethorphan and quinidine sulfate in an oral formulation, with deuterium in the dextromethorphan molecule, a heavier and stable isotope of hydrogen, in order to increase this drug’s half-life (Gant, 2014). A phase II, multicenter, randomized, double-blind, placebo-controlled study assessed the efficacy, safety, and tolerability of DXMQ as adjunctive therapy in patients with MDD and inadequate response to antidepressant treatment (N = 206 participants) (NLM, NCT02153502). The primary outcome was the change in the MADRS score during the 10 weeks of the trial (NLM, NCT02153502). No results have been yet posted as of February 2022 (Figure 4).

The co-formulation of buprenorphine and samidorphan (ALKS-5461) associates a μ-opioid receptor partial agonist and κ-opioid receptor antagonist with potential antidepressant activity (buprenorphine) and a μ-opioid receptor antagonist with low intrinsic κ- and δ-receptor modulation (samidorphan), which is intended to decrease the risk of buprenorphine abuse and dependence (Thase et al., 2019).

A phase II, multicenter, randomized, double-blind, placebo-controlled, two-stage sequential parallel comparison trial enrolled adults with MDD who had an inadequate response to 1–2 courses of antidepressant treatment (Fava et al., 2016). Participants (N = 142) were randomized to adjunctive treatment with 2/2 mg BUP/SAM, 8/8 mg BUP/SAM, or placebo, and they were monitored using HAMD, MADRS, and the CGI-S for 4 weeks, then they followed a 1-week taper (Fava et al., 2016). Compared to the placebo group, significant improvements were reported in patients treated with 2/2 mg BUP/SAM across the three depression outcome measures, and evidence of improvement was also found in the 8/8 mg BUP/SAM group, but without achieving statistical significance (Fava et al., 2016). The overall tolerability was good, and there was no evidence of opioid withdrawal when treatment was discontinued (Fava et al., 2016).

In the FORWARD-3 trial, adult patients with MDD and inadequate response to antidepressant therapy (N = 399 participants in group 1 and 30 in group 2) were randomized in a double-blind manner to 2/2 mg bupropion/samidorphan
(BUP/SAM) or placebo for 6 weeks (Zajecka et al., 2019). There were no differences in the MADRS-based response or remission rates between groups, and the least-square mean change in the MADRS total score at the end of treatment was not significantly different from placebo, although BUP/SAM did improve the overall depressive symptoms severity (Zajecka et al., 2019). Adverse events were mild or moderate in severity, and no evidence of abuse potential during treatment was detected (Zajecka et al., 2019).

Two global, multicenter, randomized, double-blind, placebo-controlled, sequential parallel-comparison design studies (FORWARD-4 and FORWARD-5) evaluated the safety and tolerability of 2/2 mg ALKS-5461 as an adjunctive treatment for MDD in adults who did not present an adequate response to antidepressant therapy ($N_1 = 385$ participants, and $N_2 = 407$ participants) (Fava et al., 2020). FORWARD-4 also evaluated a 0.5/0.5 mg dose and FORWARD-5 a 1/1 mg dose for 5 weeks during the first stage and 6 weeks during the second stage (Fava et al., 2020). FORWARD-5 achieved the primary endpoint because 2/2 mg BUP/SAM was superior to placebo, according to the MADRS total score and MADRS-6 (Bech) score change from baseline to the last visit (Fava et al., 2020). However, FORWARD-4 did not achieve the primary endpoint, although separate analyses showed significant differences between groups at other time points (Fava et al., 2020). The pooled analysis of these two trials demonstrated a greater reduction in MADRS total scores from baseline to week 3 to the end of the study (Fava et al., 2020). The overall tolerability of BUP/SAM was good,

### Table 1: Inclusion and Exclusion Criteria

| Operational criteria | Inclusion criteria | Exclusion criteria |
|----------------------|-------------------|-------------------|
| **Population**       | Selected population groups were allowed-adolescents and adults. No superior age limit was specified. The main diagnoses were major depressive disorder and bipolar depression. Treatment-resistant forms, first mood episodes, or chronic depression were included. Chronic organic co-morbidities were allowed. Diagnoses should be based on criteria specified by the authors of that paper/sponsors of the trial. Both ICD10 and DSM (IV, IV-TR, or 5) diagnosis criteria were allowed. | Studies that did not specify age limits for their samples, and studies that enrolled children. The presence of psychiatric comorbidities with significant impact on cognition, mood, behavior, and overall functionality (e.g., psychotic disorders, severe neurocognitive disorders, substance use disorders). |
| **Intervention**     | Pharmacological, or combined, pharmacological and psychotherapeutic interventions. New investigational drugs, or repurposed drugs for antidepressant use were included. | Psychotherapy as monotherapy for MDD/bipolar depression. Already marketed antidepressants, FDA-approved for all the indications specified in the „population” section of this table. Investigational products with monoaminergic, orexigenic, GABA-ergic, neurosteroid and anti-inflammatory mechanisms of action were not allowed (they are part of the first section of this review, presented elsewhere). |
| **Environment**      | Both in-patient and out-patient regimens. | Unspecified environment. |
| **Primary and secondary variables** | Evaluation of the efficacy, safety, and tolerability of new investigational drugs with antidepressant properties. | All research using unspecified variables. Reviews without pre-defined quantifiable objectives, or poorly defined primary outcome measures. |
| **Study design**     | Any phase of clinical investigation, from I to III was admitted if it corresponded to the pre-defined objective of this review. Phase IV studies were permitted, if specific variables related to depression were included, for drugs not approved for this indication. | Studies with unspecified or poorly defined design. Studies with unclearly defined populations or statistical methods used. Case reports, case series. |
| **Language**         | Any language of publication was admitted if the in-extenso published paper was available. For clinical trials identified in metadata repositories, the same language criteria were applied. |  |

**FIGURE 4** | Inclusion and exclusion criteria.

---

18

Frontiers in Pharmacology | www.frontiersin.org June 2022 | Volume 13 | Article 884155

Vasiliu Antidepressants in the Pipeline (II)
with most adverse events being of mild or moderate severity. There was minimal evidence of abuse and no evidence of dependence or opioid withdrawal by adverse events report or objective measures (Fava et al., 2020). FORWARD-1 was a phase III, randomized, double-blind trial that evaluated the safety and tolerability of two titration regimens for ALKS-5641 as adjunctive treatment in MDD adults with inadequate response to antidepressant therapy (N = 66 patients) (NLM, NCT02085135). No results were published, but according to the raw data presented on the clinicaltrial.gov archive, no SAE were recorded in either group, while 67.65% of the subjects who received 1-week titration and 87.5% of those with 2-week titration had adverse events during the 8 weeks of monitoring (NLM, NCT02085135).

FORWARD-2 was an open-label, 52-week study to evaluate the long-term safety and tolerability of BUP/SAM 2/2 mg as adjunctive therapy to ongoing antidepressant treatment for MDD patients unresponsive to prior antidepressant therapy (N = 1486 participants) (Thase et al., 2019).

Adverse events were reported by 75.7% of the patients, but the majority were of mild or moderate intensity (Thase et al., 2019). The most common adverse events were nausea, headache, constipation, and dizziness (Thase et al., 2019). Discontinuation due to adverse events was recorded in 10.4% of the cases, and SAE were reported in 3.2% of the patients (Thase et al., 2019). Following abrupt BUP/SAM discontinuation, the incidence of opioid withdrawal symptoms was low (6.5%) (Thase et al., 2019). Improvements in MADRS scores were maintained until the last visit, suggesting durability of antidepressant effect in patients receiving continuous treatment (Thase et al., 2019).

Another randomized, placebo-controlled, double-blind, phase IIIb trial evaluated the efficacy, safety, and tolerability of adjunctive ALKS-5641 in patients with treatment-refractory MDD (N = 278 participants) (NLM, NCT03188185). This study had a sequential parallel comparison design: in stage 1, subjects were randomized to ALKS-5641 or placebo, and in stage 2, only placebo non-responders from stage 1 were re-randomized to active drug or placebo (NLM, NCT03188185). The results posted on clinicaltrials.gov show non-significant differences between groups according to the main outcome measure, MADRS score (p = 0.128) (NLM, NCT03188185). The overall tolerability was good, with no SAE recorded in either stage of this trial, while the most reported adverse events within the ALKS-5641-treated patients were nausea, constipation, vomiting, fatigue, dizziness, somnolence, headache, and sedation (NLM, NCT03188185).

In conclusion, various formulations of combined pharmacological agents have been investigated for MDD or TRD, with positive results for AXS-05 (although a negative phase III trial also exists) and DMXQ (a single-phase IIa trial) but controversial results for ALKS-5641 (phase II and III trials) (Table 3).

**Cholinergic Receptor Modulators**

Pharmacological interventions targeting nicotinic receptors have been explored in multiple psychiatric disorders, for example, MDD, neurocognitive disorders, nicotine use disorder, or schizophrenia (Davidson et al., 2021). JNJ-39393406 is an investigational product with properties of α7 nicotinic receptors selective positive allosteric modulator, and it can lower agonist and nicotine threshold for activation of these receptors 10–20-fold while increasing the maximum agonist response 17–20-fold (Davidson et al., 2021). In a randomized, double-blind, placebo-controlled, add-on to psychotropics, parallel-group trial, 71 patients diagnosed with MDD were monitored for 2 weeks (Davidson et al., 2021). The primary outcome measures were the Brief Assessment of Cognition in Schizophrenia (BACS) composite score and the MADRS scores (Davidson et al., 2021). No significant difference for the primary outcomes was detected at the end of the study, nor for the secondary outcomes (Davidson et al., 2021). The overall tolerability of JNJ-39393406 was good, without differences in the adverse events rate between active drug and placebo groups (Davidson et al., 2021).

Ropanicant (SUVN-911) is a potent α4β2 receptor ligand with oral bioavailability, good brain penetration, and marked antidepressant activity in animal models of depression (Nirogi et al., 2020). A phase I, single-center, open-label, single-dose study evaluated the effect of food, gender, and age on the safety and pharmacokinetic profile of SUVN-911, administered orally in healthy subjects (N = 28 participants), but results are not available (NLM, NCT03551288). Another phase I, double-blind, placebo-controlled, single-center clinical study explored the safety, tolerability, and pharmacokinetic profile of single and multiple doses of orally administered SUVN-911 or placebo to healthy male subjects (N = 64), but no results are available for this study either (NLM, NCT03155503).

Scopolamine is a competitive inhibitor of post-ganglionic muscarinic receptors for acetylcholine, and it acts as a nonselective muscarinic antagonist (Zhang et al., 2017). The effects of scopolamine hydrobromide administration (4 μg/kg i.v.) were evaluated in two trials, a double-blind, placebo-controlled, dose-finding study followed by a double-blind, placebo-controlled, crossover clinical trial (Furey and Drevets, 2006). Adult outpatients diagnosed with MDD or bipolar disorder (N = 19) received multiple sessions of i.v. infusions of placebo or scopolamine hydrobromide, and these sessions were 3–5 days apart (Furey and Drevets, 2006). Patients who received a placebo followed by scopolamine showed no significant change in the main outcomes (MADRS and HAMA scores) during the placebo phase, but significant reductions in both depression and anxiety rating scores were observed after scopolamine administration (Furey and Drevets, 2006). Patients who received scopolamine first and placebo second also showed significant reductions in depression and anxiety rating scale scores after scopolamine i.v., relative to baseline, and these effects persisted during the placebo phase (Furey and Drevets, 2006).

Outpatients with MDD (N = 23) were enrolled in a double-blind, placebo-controlled, crossover trial, and they were randomized into either a placebo-scopolamine or a scopolamine-placebo sequence (Drevets and Furey, 2010). Scopolamine was administered in 4 μg/kg i.v dose, in repeated
**TABLE 3 | Combinations of pharmacological agents with antidepressant properties in the pipeline.**

| Authors | Methodology | Results | Clinical trial phase, trial identifier (if available) |
|---------|-------------|---------|------------------------------------------------------|
| NLM (2014b) | AXS-05 vs. bupropion, DBRCT, N = 80 moderate-to-severe MDD patients, 6 weeks | Change in the MADRS score was the primary outcome, and the rate of remission and response was superior for the AXS-05 group at the end-point, with early separation from the bupropion-treated group. The pharmacological combination was safe and well-tolerated. The most frequent treatment-related AE were nausea, dizziness, dry mouth, decreased appetite, and anxiety | Phase II, NCT03595579 |
| NLM (2021) | AXS-05 vs. placebo, DBRCT, N = 44, TRD patients, 52 weeks | AXS-05 met the primary endpoint by significantly delaying the time to relapse of depressive symptoms compared to placebo, with no relapse over at least 6 months. Also, the active medication met the key secondary endpoint of relapse prevention | Phase II, NCT04608396 |
| NLM (2020) | AXS-05 vs. placebo, DBRCT, N = 327 moderate-to-severe MDD patients, 6 weeks | AXS-05 significantly decreased patient-reported depressive symptoms, evaluated by QIDS-SR-16 and PG1-I, compared to placebo at week 6. The response on QIDS-SR-16 total score was significantly greater for AXS-05 starting from week 1 and at every time point thereafter, with 53.4% of patients achieving response compared to 33% of placebo patients at week 6 | Phase III, NCT04019704 |
| Biospace (2020) | AXS-05 vs. bupropion, DBRCT, N = 312 TRD patients, 6 weeks | The change in MADRS total score was not significantly different between the two groups. The secondary outcomes favored, however, AXS-05 vs. active control, with significantly higher rates of remission from depression at week 1 and at every time point thereafter. AXS-05 improved cognitive function and reduced anxiety symptoms | Phase III, NCT02741791 |
| Murrough et al. (2017) | DXM0, open-label, N = 20 TRD patients, 10 weeks | MADRS score (primary outcome) significantly decreased from baseline to endpoint. The QIDS-SR score also decreased significantly during DXM0 treatment, and the response and remission rates in the intent-to-treat sample were 45% and 35%, respectively | Phase IIa, NCT01882829 |
| Kelly and Lieberman (2014) | DXM0 + ongoing antidepressant, retrospective, N = 77 treatment-resistant BD type II/NOS patients | On day 90, the CGI-I score was 1.66, and some patients improved their clinical status within 1–2 days after the beginning of DXM0 administration. An important number of patients (N = 19) discontinued treatment due to AE, mainly nausea | Phase N/A |
| NLM (2014a) | AVP-786 vs. placebo as adjunctive to current therapy, DBRCT, N = 206 MDD patients with inadequate response to antidepressants, 10 weeks | The primary outcome was MADRS total score. | Undisclosed results |
| Fava et al. (2016) | ALKS-5461 vs. placebo, DBRCT, N = 142 MDD patients with inadequate response to antidepressant therapy, 5 weeks | Significant improvements were reported in patients treated with 2/2 mg BUP/SAM in HAMD, MADRS, and CGI-S, and evidence of improvement was also found in the 8/8 mg BUP/SAM group, but without achieving statistical significance. The overall tolerability was good | Phase II, NCT01500200 |
| Zanella et al. (2019) | ALKS-5461 vs. placebo as adjunctive therapy, N = 399 + 30, MDD patients with inadequate response to antidepressant treatment, 6 weeks | There were no differences in MADRS-based response or remission rates between groups, and the LSM change in MADRS total score at the end of treatment was not significantly different from placebo, although BUP/SAM did improve the overall depressive symptoms severity. | Phase III, NCT02158546 |
| Fava et al. (2020) | ALKS-5461 as adjunctive therapy to ongoing antidepressant, N = 385, and 407 MDD patients, respectively, 5 + 6 weeks (two stages) | One of these trials achieved its primary outcome (MADRS total score and Bech–6 score change from baseline to week 6), while the other did not. The pooled analysis of these two trials demonstrated a greater reduction in MADRS total scores from baseline for 2/2 mg BUP/SAM vs. placebo from baseline at multiple time points, including the last visit, and a significant average change from baseline to week 3 to the end of study. The overall tolerability was good | Phase III, NCT02158533, Phase III, NCT02218908 |
| NLM (2014b) | ALKS-5461 two titration doses adjunctive to ongoing treatment, N = 66 MDD patients with inadequate response to treatment, 8 weeks | No SAE were recorded in either group of titration, while 67.65% of the subjects who received 1-week titration and | Phase III, NCT02085135 |

(Continued on following page)
sessions, 3–5 days apart (Drevets and Furey, 2010). MADRS scores decreased by 32% in patients who received first scopolamine (p < 0.001) versus those who received the placebo first, and improvement was significant at the first evaluation that followed scopolamine administration (Drevets and Furey, 2010). Scopolamine administration was associated with drowsiness, blurred vision, dry mouth, lightheadedness, and reduced blood pressure, and no participant dropped out due to side effects (Drevets and Furey, 2010).

In a double-blind, randomized, controlled, phase IV trial, 14 MDD participants received either scopolamine 0.15 mg b.i.d and naltrexone 1 mg b.i.d for 4 weeks or placebo, and they were monitored for 4 weeks (NLM, NCT03386448). According to the results posted by the sponsor, the change of MADRS scores from baseline to the end of the study visit (the primary outcome) was significant in favor of the scopolamine and naltrexone group (p = 0.03), and the rate of adverse events in the active group was 25% (mainly nausea) versus 0% in the placebo group (NLM, NCT03386448).

A randomized, double-blind, placebo-controlled, phase II trial focused on the evaluation of i.v. scopolamine in patients with bipolar disorder who experience a depressive episode of at least moderate severity is ongoing as of April 2022 (NLM, NCT04211961). The main outcome is the change in the HAMD score at 2 weeks, and the recruitment target is 50 participants (NLM, NCT04211961).

A randomized, controlled trial had the objective of comparing the effects of ketamine + placebo, scopolamine + placebo, and ketamine + scopolamine in patients with treatment-resistant MDD, monitored for up to 4 months, but this study was withdrawn due to lack of funding (NLM, NCT01613820).

A randomized, placebo-controlled, phase II study evaluated the efficacy of i.v. scopolamine (4 μg/kg) in seven patients diagnosed with MDD who are receiving electroconvulsive therapy (ECT) (NLM, NCT01312844). According to the unpublished results posted on clinicaltrials.gov, scopolamine was not significantly superior to placebo in any of the primary outcomes: the change in the HAMD-17 scores was −17.5 versus −14.0 (scopolamine vs. placebo) at the time of ECT completion (about 2 weeks), the mean time to response for patients receiving ECT was 8.33 vs. 5.0 days, and the mean number of ECT sessions to achieve response/remission were 2.33 vs. 2.5/10 versus 6.5 (scopolamine vs. placebo) (NLM, NCT01312844).

In another double-blind, placebo-controlled, phase IV clinical trial, 66 adult outpatients with severe MDD were randomized on 1) scopolamine 0.3 mg/ml i.m. in the morning and placebo i.m. in the afternoon, 2) scopolamine 0.3 mg/ml i.m. twice daily, or 3) placebo i.m. (0.9% saline) twice daily (NLM, NCT03131050). All patients also received 10 mg/day of escitalopram for 4 weeks of treatment (NLM, NCT03131050). No results of this trial have been yet released.

In conclusion, targeting cholinergic neurotransmission as a key mechanism for antidepressant activity is supported by several trials, but most of the research on this pharmacodynamic mechanism is still in its early phase (Table 4).

### Other Agents
Animal studies suggest a possible role of microtubule-associated protein type-2 (MAP-2) as a target for the treatment of depressive disorders due to the association of this pathology with neuronal abnormalities in brain microtubule function, including changes in α-tubulin isoforms (Bianchi and Baulieu, 2012). The synthetic pregnenolone-derivative MAP4343 (3ß-methoxy-pregnenolone) binds to MAP-2 in vitro and increases its ability to stimulate tubulin assembly (Bianchi and Baulieu, 2012). The effects of a single injection of MAP4343 and fluoxetine in naïve Sprague Dawley rats were compared, with positive results for the investigational product (Bianchi and Baulieu, 2012). The MAP4343 had efficacy in the rat forced swimming test, the most widely used model of depression, by decreasing immobility behavior (Bianchi and Baulieu, 2012). These antidepressant effects were accompanied by

| TABLE 3 | (Continued) Combinations of pharmacological agents with antidepressant properties in the pipeline. |
| Authors | Methodology | Results | Clinical trial phase, trial identifier (if available) |
|----------|-------------|---------|-----------------------------------------------|
| Thase et al. (2019) | ALKS-5461 as adjunctive therapy, open-label, N = 1486 MDD patients unresponsive to prior antidepressant therapy, 52 weeks | 87.5% of those with 2-week titration had AE during the study | Phase III, NCT02141399 |
| NLM (2017d) | ALKS-5461 vs. placebo adjunctive to current treatment, N = 278 TRD patients, 5 + 6 weeks (two stages) | Non-significant differences between groups were reported according to the main outcome measure, MADRS total score. The overall tolerability was good, with no AE recorded in either stage of this trial | Phase IIIb, NCT03188185 |

AE, adverse events; DBRCT, double-blind, randomized controlled trial; DXMQ, dextromethorphan hydrobromide and quinidine; HAMD, Hamilton Depression Rating Scale; MADRS, Montgomery Asberg Depression Rating Scale; MDD, major depressive disorder; PGI-I, Patient Global Impression of Improvement; QIDS-SR, Quick Inventory of Depressive Symptomatology-Self-Report; SAE, severe adverse events; TRD, treatment-resistant MDD.
### TABLE 4 | Cholinergic receptor modulators and other agents with antidepressant properties in the pipeline.

| Authors                          | Methodology                                                                 | Results                                                                                                                                                                                                 | Clinical trial phase, trial identifier (if available) |
|----------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| Davidson et al. (2021)           | JNJ-39393406 vs. placebo as add-on, DBRCT, N = 71 MDD patients, 2 weeks    | No significant differences between groups in BACS composite score or MADRS total score were reported at week 2. The overall tolerability was good. Unpublished results. | Phase II, NCT02677207                                  |
| NLM (2018h)                      | Ropanicant (SUVPN-911), open-label, single-dose study, N = 28 healthy subjects | Primary outcome measure is AUC. Results have not been yet disclosed.                                                                                                                                  | Phase I, NCT03551288                                  |
| NLM (2017e)                      | SUVPN-911 vs. placebo, single/multiple doses, DBRCT, N = 64 healthy male subjects | Primary outcome measures - ECG, vital signs, C-SSRS. Results have not yet been disclosed.                                                                                                                  | Phase I, NCT03155503                                  |
| Furey and Drevets (2006)         | Scopolamine 4 μg/kg i.v. vs. placebo, two DBRCTs, N = 19 MDD/BD patients, repeated sessions 3–5 days apart | Patients who received placebo followed by scopolamine showed no significant change in the main outcomes (MADRS and HAMA scores) during the placebo phase, but significant reductions in both outcomes were observed after scopolamine administration. Patients who received scopolamine first and placebo second also showed significant reductions in depression and anxiety rating scale scores after scopolamine i.v., relative to baseline, and these effects persisted during the placebo phase. | Phase II, NCT00369915                                  |
| Drevets and Furey (2010)         | Scopolamine 4 μg/kg i.v. vs. placebo, DBRCT, N = 23 MDD outpatients, repeated sessions 3–5 days apart | MADRS scores decreased by 32% in patients who received first scopolamine (p < 0.001) vs. those who received the placebo first, and improvement was significant at the first evaluation that followed scopolamine administration. Scopolamine administration was associated with drowsiness, blurred vision, dry mouth, lightheadedness, and reduced blood pressure, and no participant dropped out due to side effects. | Phase II, NCT03386448                                  |
| NLM (2017f)                      | Scopolamine 0.15 mg b.i.d. + naltrexone 1 mg b.i.d. vs. placebo, DBRCT, N = 14 MDD patients, 4 weeks | Unpublished results support a significant change of the MADRS scores from baseline to the end of the study visit (the primary outcome) in favor of the scopolamine and naltrexone group (p = 0.03), and the rate of adverse events in the active group was 25% (mainly nausea) vs. 0% in the placebo group. | Phase IV, NCT03386448                                  |
| NLM (2019c)                      | Scopolamine i.v. vs. placebo, DBRCT, N = 50 (recruitment target), 2 weeks   | The main outcome is the change in HAMD score at 2 weeks. The trial is ongoing.                                                                                                                          | Phase II, NCT04211961                                  |
| NLM (2012d)                      | Ketamine + placebo, scopolamine + placebo, and ketamine + scopolamine, DBRCT, N = 0 MDD participants, 4 months | This study was withdrawn due to a lack of funding.                                                                                                                                                      | N/A, NCT01613820, Phase II, NCT01312844               |
| NLM (2011a)                      | Scopolamine 4 μg/kg i.v. vs. placebo + ECT, DBRCT, N = 7 MDD patients, 2 weeks | Unpublished results suggest that scopolamine was not significantly superior to placebo in any of the primary outcomes: the change in the HAM-D-17 scores was −17.5 vs. −14.0 (scopolamine vs. placebo) at the time of ECT completion (about 2 weeks); the meantime for response for patients receiving ECT was 8.33 vs. 5.0 days, and the mean number of ECT sessions to achieve response/remission was 2.33 vs. 2.5/10 vs. 6.5 (scopolamine vs. placebo). | Phase II, NCT01312844                                  |
| NLM (2017g)                      | Scopolamine 0.3 mg/mL or 0.6 mg/mL i.m. vs. placebo + escitalopram 10 mg/day, DBRCT, N = 66 outpatients with severe MDD, 4 weeks | No results of this trial have been yet released.                                                                                                                                                       | Phase IV, NCT03131050                                  |
| Other agents                     |                                                                             |                                                                                                                                           |                                                       |
| Davidson et al. (2021)           | JNJ-39393406 vs. placebo as add-on, DBRCT, N = 110 (estimated), TRD patients, 42 days | The primary outcome measure is HAMD’s total score change. The results of this trial have not yet been disclosed. Response rates (based on CGI ratings of much or very much improved) were 26% for gabapentin, 52% for lamotrigine, and 23% for placebo. The overall tolerability of gabapentin was good. | Phase II, NCT03870776                                  |
| Fye et al. (2000)                | Gabapentin vs. lamotrigine vs. placebo, N = 31 treatment-resistant MDD and BD patients, 6 weeks | Pregabalin significantly improved HADS score, both anxiety and depression scale scores, Fibromyalgia Impact Questionnaire total score, but not EuroQol 5-dimensions scores. | Phase N/A, NCT03870776                                  |
| Arnold et al. (2015)             | Pregabalin vs. placebo + SSRI/SNRi, cross-over DBRCT, N = 197 fibromyalgia + depression patients, periods of 2 × 6 week | AE were reported in 56% of the patients, and the most frequently reported was headache (18.6%). The primary outcome measure is MADRS total score change. The trial is ongoing. | Phase I, NCT02475148                                  |
| Timmers et al. (2018)            | JNJ-54175446 vs. placebo, SAD, N = 77 healthy participants                  |                                                                                                                                           | Phase II, NCT04116606                                  |
| NLM (2019d)                      | JNJ-54175446 vs. placebo, DBRCT, N = 142 (estimated), MDD patients with incomplete response to antidepressants, 8 weeks |                                                                                                                                           |                                                       |

(Continued on following page)
### TABLE 4 | (Continued) Cholinergic receptor modulators and other agents with antidepressant properties in the pipeline.

| Authors | Methodology | Results | Clinical trial phase, trial identifier (if available) |
|---------|-------------|---------|------------------------------------------------------|
| **Cholinergic agents** | | | |
| Brin et al. (2020) | OnabotulinumtoxinA (onabotA) 30U/50U vs. placebo, DBRCT, N = 255 MDD patients, 24 weeks | Onabot 30U approached significance vs. placebo, according to the MADRS scores change, and reached significance at weeks 3 and 9, with secondary endpoints also reaching significance at several time points. The overall tolerability was good | Phase II, NCT02116381 |
| NLM (2011b) | OnabotA (29–40 U) vs. placebo, DBRCT, N = 30 MDD patients, 6 weeks | Patients were monitored using HAMD-21, and the change in the active drug followed by placebo group was significant vs. placebo followed by active drug (−12.7 vs. −0.4) at 12 weeks (p < 0.001). No SAE were recorded in either group | Phase II, NCT01392963 |
| Finzi and Rosenthal (2014) | OnabotA (29U/40U), vs. placebo, DBRCT, N = 85 MDD patients, 6 weeks | Response rates (based on MADRS scores) at 6 weeks from the injection date were 52% and 15% in the onabotA vs. placebo groups (p < 0.001). The remission rate (also based on MADRS score) was 27% vs. 7% in the onabotA vs. placebo | Phase IV, NCT01556971 |
| NLM (2018) | OnabotA vs. placebo, DBRCT, N = 58 (estimated), TRD patients, 6 weeks | The main outcome measure is the proportion of patients with improvement of depressive symptoms based on the MADRS scale at 6 weeks after injection. The trial is ongoing | Phase III |
| NLM (2009b) | OnabotA (20–50 U), open-label, N = 50, MDD and non-depressed individuals, 12 weeks | BDI score change was −14.9 in the MDD group at week 12 vs. −2.7 in the healthy volunteers, while the self-esteem improved by three points on RSES vs. −0.4 in the healthy participants at the endpoint. The quality of life (WHOQOL-BREF) improved in the MDD group with 0.5 points at week 12 compared to baseline, and 0.2 points in the comparator group | Phase IV, NCT01004042 |
| Monti et al. (2019) | PH-10 low-dose/high-dose vs. placebo, DBRCT, N = 30 MDD patients, 9 weeks | HAMD-17 total score change at endpoint vs. baseline showed a trend for difference (p = 0.07), with a greater reduction of depression severity scores for high dose PH-10 vs. placebo. The positive effects of PH-10 were recorded from week 1 for the high dose (p = 0.03). No SAE were reported, and the overall tolerability was good | Phase IIa |
| Binneman et al. (2006) | CP-316,311 vs. placebo vs. sertraline, DBRCT, N = 167 recurrent MDD patients, 6 weeks | The change from baseline in the HAMD score at the final visit was not significantly different between the investigational product group and placebo group, although sertraline did differentiate itself from the placebo | Phase II, NCT00143091 |
| Zobel et al. (2000) | R121919, open-label, N = 24 MDD patients, 30 days | The drug was safe and well-tolerated within the 30-day observation period. It induced reductions in depression and anxiety scores using clinician-rated and patient-scored instruments (HAMD, BDI, HAMA, CGI, STAI) | Phase IIa |

AE: adverse events; BD: bipolar depression; BDI: Beck Depression Inventory; CGI: Clinical Global Impression; DBRCT: double-blind, randomized controlled trial; ECT: electroconvulsive therapy; HADS: Hospital Anxiety and Depression Scale; HAMA: Hamilton Anxiety Rating Scale; HAMD: Hamilton Depression Rating Scale; MADRS: Montgomery-Asberg Depression Rating Scale; MDD: major depressive disorder; PG-I: Patient Global Impression of Improvement; QIDS-SR: Quick Inventory of Depressive Symptomatology-Self-Report; RSES: Rosenberg Self-Esteem Scale; SAD: single ascending dose; SAE: severe adverse events; SNRI: serotonin and norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitors; STAI, State-Trait Anxiety Inventory; TRD: treatment-resistant MDD; WHOQOL-BREF: World Health Organization Quality of Life-BREF.

Modifications of α-tubulin isoforms in the hippocampus, amygdala, and prefrontal cortex (Bianchi and Baulieu, 2012). A phase II, double-blind, randomized, placebo-controlled, parallel, multicentric trial was planned to enroll 110 adult patients with TRD (NLM, NCT03870776).

**Gabapentinoids** modulate α28 subunits of voltage-gated calcium channels and have been explored in numerous psychiatric disorders, MDD included (Vasiliu et al., 2017). A double-blind, randomized, crossover, placebo-controlled study compared the efficacy of gabapentin and lamotrigine monotherapy versus placebo in 31 patients with refractory unipolar or bipolar mood disorders who were monitored for 6 weeks (Frye et al., 2000). Response rates (based on CGI ratings of much or very much improved) were 26% for gabapentin, 52% for lamotrigine, and 23% for placebo, with a Cochran’s Q post hoc difference between gabapentin and placebo of 0.08 (p = 0.70) (Frye et al., 2000). The overall tolerability of gabapentin was good (Frye et al., 2000).

A randomized, placebo-controlled, double-blind, 2-period, 2-way crossover study was composed of two 6-week treatment periods, separated by 2 weeks of taper/wash-out phases, and recruited 197 patients diagnosed with fibromyalgia taking a stable dose of SSRI or serotonin and norepinephrine reuptake inhibitor (SNRI) for comorbid depression (Arnold et al., 2015). These patients were randomized on pregabalin/placebo or placebo/pregabalin (300–450 mg/day) as an adjuvant to the
current antidepressant treatment (Arnold et al., 2015). Pregabalin significantly improved Hospital Anxiety Depression Scale (HADS) score, both anxiety and depression scales scores, and Fibromyalgia Impact Questionnaire total score but not EuroQoL 5-dimensions scores (Arnold et al., 2015).

Microglial cells within the central nervous system are presumedly involved in the neuroinflammation that has been associated with multiple neuropsychiatric disorders (Bhattacharya and Ceusters, 2020). Neuroinflammatory drug targets on microglia cells within the central nervous system have been of interest, especially in the last decades. JNJ-54175446 is a brain penetrant-P2X7 antagonist agent which targets an ATP-activated ion channel, abundantly expressed on microglia and peripheral immune cells (Bhattacharya and Ceusters, 2020). In a first-in-human, placebo-controlled, single ascending dose study, JNJ-54175446 demonstrated in healthy participants (N = 77) dose-dependent increases in plasma exposure, cerebrospinal fluid exposure, and ex vivo inhibition of IL-1β from human blood (Timmers et al., 2018). Adverse events were reported in 56% of the participants, of which the most frequently reported was headache (18.6%) (Timmers et al., 2018). A phase II, randomized, placebo-controlled, double-blind trial of the antidepressant efficacy of JNJ-54165446 in patients with MDD and incomplete response to monoaminergic antidepressants is currently ongoing, and as the main outcome, it has measured the change in the MADRS score from baseline to week 8 (NLM, NCT04116606).

Another approach to MDD treatment involves nonsystemic options, with the main benefit of avoiding the onset of adverse events and potentially dangerous pharmacokinetic interactions frequently associated with orally administered classical antidepressants. Local injections of onabotulinumtoxinA (onabota, BOTOX) may determine muscle relaxation through a complex process involving the cleaving of SNAP-25 (synaptosomal-associated protein-25 kD) (Brin et al., 2020). The consequence of this process is a lack of neurotransmitter content released from the vesicles in the synaptic cleft, including acetylcholine from motor neurons (Brin et al., 2020).

A 24-week multicenter, randomized, double-blind, placebo-controlled, two-cohort, parallel-group, phase II clinical trial evaluated the effects of 30 and 50 U onabota in outpatients female patients (N = 255) with MDD (Brin et al., 2020). The investigational product or placebo was divided into six or eight glabellar injections (Brin et al., 2020). Onabot 30U approached significance versus placebo, according to the MADRS scores change, and reached significance at weeks 3 and 9, with secondary endpoints also reaching significance at several time points (Brin et al., 2020). Onabot 50U did not separate at week 6 from placebo in any variables (Brin et al., 2020). The overall tolerability was good, and the most commonly reported adverse events (5% in either of the active treatment groups) were headache, upper respiratory infections, and eyelid ptosis (Brin et al., 2020). OnabotA 30U administered in a single injection during a unique session had a consistent efficacy signal across multiple depression symptom scales for at least 12 weeks (Brin et al., 2020).

In a phase II, randomized, double-blind, cross-over trial, 30 patients diagnosed with MDD received an injection of clostridium botulinum toxin type A neurotoxin complex (29–40 U total injection) in the glabella region or placebo, and after 3 months, they received a placebo injection or Botox to the same region (NLM, NCT01392963). Patients were monitored using HAMD-21, and the change in the active drug followed by placebo group was significant versus placebo followed by active drug (−12.7 vs. −0.4) at 12 weeks (p < 0.001) (NLM, NCT01392963). No SAE were recorded in either group (NLM, NCT01392963).

In a phase IV, randomized trial, a single dose of onabotulinumtoxinA (29 U for females or 40 U for males) or placebo injections was administered into corrugator and procerus frontal muscles in 85 patients diagnosed with MDD (Finzi and Rosenthal, 2014). Response rates (MADRS scores decreased by ≥50%) at 6 weeks from the injection date were 52% and 15% in the onabota versus placebo groups (p < 0.001) (Finzi and Rosenthal, 2014). The remission rate (MADRS score < 10) was 27% versus 7% in the onabota versus placebo (Finzi and Rosenthal, 2014).

Another ongoing trial is investigating the effect of onabota injection in the corrugator and procerus muscle in patients with TRD in comparison to the infiltration in the crow’s feet area, in addition to the current antidepressant treatment (NLM, NCT03484754). The estimated enrollment is 58 participants, and the main outcome measure is the proportion of patients with improvement of depressive symptoms based on the MADRS scale at 6 weeks after injection (NLM, NCT03484754).

Quality of life, depressive symptoms, and self-esteem were the main outcomes in a phase IV, non-randomized, open-label trial, which enrolled 50 patients diagnosed with MDD versus non-depressed subjects who received onabota injections of 20–40 U in five points of the glabellar area (NLM, NCT01004042). The change in BDI scores was −1.49 in the MDD group at week 12 versus −2.7 in the healthy volunteers, while the self-esteem improved by three points on the Rosenberg Self-Esteem Scale versus −0.4 in the healthy participants at endpoint (NLM, NCT01004042). The quality of life (WHOQOL-BREF score) improved in the MDD group with 0.5 points at week 12 compared to baseline and 0.2 points in the comparator group (NLM, NCT01004042).

PH-10 is a synthetic, odorless neuroactive steroid from the family of pherines, formulated for intranasal administration (Monti et al., 2019). It engages nasal chemosensory receptors and modulates neural circuits in the limbic amygdala and other basal forebrain structures, inducing antidepressant-like effects (Monti et al., 2019). In a single site exploratory phase IIa study, 30 patients with MDD were randomized to 8 weeks of self-administered intranasal PH10 low dose (3.2 μg), high dose (6.4 μg), or placebo (Monti et al., 2019). The analysis of HAMD-17 changes at endpoint versus baseline showed a trend for difference (p = 0.07), with a greater reduction of depression severity scores for high dose PH10 versus placebo (Monti et al., 2019). The positive effects of PH10 were recorded starting from week 1 for the high dose (p = 0.03) (Monti et al., 2019). No serious adverse effects were reported, and the overall tolerability was good (Monti et al., 2019).
Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis has been suggested as an important pathogenetic mechanism in MDD, but up to date, there are no drugs targeting this system approved for use in patients with mood disorders (Menke, 2019).

CRH-1 receptor antagonists have been investigated in patients with MDD or anxiety disorders without significant results, but several authors consider that a more homogenous group of participants in clinical trials (i.e., those with significant CRH signaling dysfunction)
may help detect a signal for these molecules (Menke, 2019). A phase II, randomized, parallel assignment, 6-week, fixed-dose, double-blind, double-dummy, placebo and sertraline controlled, multicenter trial evaluated the safety and efficacy of CP-316,311 (a selective CRH-1 antagonist) in outpatients with recurrent MDD (N = 167 participants) (Binneman et al., 2008). The efficacy of 400 mg of CP-316,311 twice daily was compared with 100 mg sertraline daily or placebo, and the interim analysis led to the trial termination (Binneman et al., 2008). The change from baseline in the HAMD score at the final visit was not significantly different between the investigational product group and placebo group, although sertraline did differentiate itself from the placebo (Binneman et al., 2008).

Another high-affinity, CRH-1 receptor antagonist, R121919, was investigated in a clinical trial (N = 24 patients with MDD), and it was safe and well-tolerated within the 30-day observation period (Zobel et al., 2000). The CRH-1 blockade did not impair the baseline corticotropin/cortisol activity, and it did not have such an effect following an exogenous CRH challenge (Zobel et al., 2000). R121919 induced reductions in depression and anxiety scores using clinician-rated and patient-scored instruments (Zobel et al., 2000).

In conclusion, these molecules with distinct pharmacodynamic properties indicate, besides the complexity of the MDD pathogenesis, the need for further exploration of different central and peripheral ways (e.g., steroid hormones, ion channel modulators, or locally administered exoproteins) to decrease the severity of depressive symptoms (Table 4).

A synthesis of the safety and tolerability data available for investigational products reviewed in this study is presented in Figure 5.

**CONCLUSION**

Multiple non-monoaminergic pathways are considered of interest in clinical research in the treatment of depressive disorders. Glutamatergic agents are by far the most extensively researched, and several sub-categories have been identified: antagonists of GluN2B subunits of NMDA receptors (seven investigational products), NMDA-receptor antagonists (14 agents), AMPA receptor potentiators (two agents), and metabotropic receptor antagonists (four agents). These agents were investigated in phases I–III of clinical trials. One estrin modulator is investigated in phases I and II of clinical trials. Combinations of pharmacological agents (i.e., AXS-05, DXMQ, AVP-786, and ALKS-5461) are investigated for their antidepressant properties in phases II and III of clinical trials. Two cholinergic agents (i.e., JNJ-39393406 and SUVN-911) are explored in phases I and II of clinical trials, but phase II trials have undisclosed results. Other agents (i.e., MAP4343, gabapentin, pregabalin, JNJ-54175446, onabotA, PH10, CP-316, 311, and R1219191) have been studied in phases I–IV clinical trials. In conclusion, there is an abundance of investigational products that reached phases II and III of clinical research, although it is too early to formulate a prognosis if any of these agents will be approved any time soon for MDD or bipolar depression.

Limitations of this review refer to the possible exclusion of antidepressants in the pipeline due to the pre-formulated criteria of this search and the lack of availability of relevant data regarding the current status of investigation for these products in the explored references.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

**AUTHOR CONTRIBUTIONS**

As the only author, I assume the entire responsibility for collecting, processing, and presenting data within this review.

**REFERENCES**

Agbo, F., Bui, K. H., and Zhou, D. (2017). Population Pharmacokinetic Analysis of Lanicemine (AZD6765), an NMDA Channel Blocker, in Healthy Subjects and Patients with Major Depressive Disorder. *J. Clin. Pharmac. Ther.* 42 (3), 539–546. doi:10.1111/jcpt.12541

Alexopoulos, G. S. (2019). Mechanisms and Treatment of Late-Life Depression. *Transl. Psychiatry* 9, 188. doi:10.1038/s41398-019-0514-6

Arnold, L. M., Sarzi-Puttini, P., Arsenault, P., Khan, T., Bhadra Brown, P., Clair, A., et al. (2015). Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-Controlled Study. *J. Rheumatol.* 42 (7), 1237–1244. doi:10.3899/jrheum.141196

Arsova, A., Möller, T. C., Vedel, L., Hansen, J. L., Foster, S. R., Gregory, K. J., et al. (2020). Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5. *Mol. Pharmacol.* 98 (1), 49–60. doi:10.1124/mol.119.119032

Axsome Therapeutics (2019). ASCEND Phase 2 Trial of AXS-05 in MDD Topline Results. Available at: https://axsometherapeuticsinc.gcs-web.com/static-files/22952a8-ab22-4dd3-b36f-08904c2c6d4b (Accessed January 28, 2022).

Axsome Therapeutics (2021). Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression. Available at: https://www.globenewswire.com/news-release/2021/08/09/2276951/33090/en/Axsome-Therapeutics-Announces-AXS-05-Achieves-Primary-and-Key-Secondary-Endpoints-in-the-MERIT-Phase-2-Trial-in-Treatment-Resistant-Depression.html (Accessed January 28, 2022).

Axsome Therapeutics (2020). Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder. Available at: https://www.globenewswire.com/news-release/2020/09/14/2097279/33090/en/Axsome-Therapeutics-Presents-New-Data-from-GEMINI-Phase-3-Trial-with-AXS-05-Demonstrating-Rapid-and-Significant-Improvements-in-Patient-Reported-Outcomes-in-Major-Depressive-Disorder.html (Accessed January 28, 2022).

Bahji, A., Vazquez, G. H., and Zarate, C. A., Jr. (2021). Comparative Efficacy of Racemic Ketamine and Esketamine for Depression: A Systematic Review and Meta-Analysis. *J. Affect Disord.* 278, 542–555. doi:10.1016/j.jad.2020.09.071
Bahr, R., Lopez, A., and Rey, J. A. (2019). Intranasal Esketamine (Spravato™) for Use in Treatment-Resistant Depression in Conjunction with an Oral Antidepressant. P T 44 (6), 340–342, 344–366, 375.

Bhattcharaya, A., and Ceusters, M. (2020). Targeting Neuroinflammation with Brain Penetrant P2X7 Antagonists as Novel Therapeutics for Neuropsychiatric Disorders. Neuropharmacology 45, 234–235. doi:10.1016/j.neuropharm.2009.11.021

Bianchi, M., and Baulieu, E. E. (2012). 3β-Methoxy-phenalenone (MAP4343) as an Innovative Therapeutic Approach for Depression Disorders. Proc. Natl. Acad. Sci. U. S. A. 109 (5), 1713–1718. doi:10.1073/pnas.1121485109

Binnewam, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., and Stiger, T. (2008). A 6-week Randomized, Placebo-Controlled Trial of CP-316,311 (A Selective CRH1 Antagonist) in the Treatment of Major Depression. Am. J. Psychiatry 165 (5), 617–620. doi:10.1176/appi.ajp.2008.07071199

Biospace (2020). Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications. Available at: https://www.biospace.com/article/releases/axsome-therapeutics-announces-topline-results-of-the-stride-1-phase-3-trial-in-treatment-resistant-depression-and-expert-call-to-discuss-clinical-implications/ (Accessed January 28, 2022).

Brennan, B. P., Hudson, J. I., Jensen, J. E., McCarthy, J., Roberts, J. L., Prescot, A. P., Burgdorf, J., Zhang, X. L., Weiss, C., Gross, A. L., Schmidt, M., Weiss, C., et al. (2010). Rapid Enhancement of Glutamatergic Neurotransmission in the Medial Prefrontal Cortex and hippocampus. Neuroscience 308, 202–211. doi:10.1016/j.neuroscience.2015.09.004

Callahan, R. J., Au, J. D., Paul, M., Liu, C., and Yost, C. S. (2004). Functional Associated with a Metaplasticity Process in the Medial Prefrontal Cortex and hippocampus. Neuroscience 308, 202–211. doi:10.1016/j.neuroscience.2015.09.004

Chen, K. T., Wu, C. H., Tsai, M. H., Wu, Y. C., Jou, M. J., Huang, C. C., et al. (2017). Pharmacology and Mechanism of Action of Riluzole. Neuropharmacology 45, 234–235. doi:10.1016/j.neuropharm.2009.11.021

Doble, A. (1996). The Pharmacology and Mechanism of Action of Riluzole. Neurology 47 (6 Suppl. 4), S233–S241. doi:10.1212/wnl.47.6_suppl.4.233s

Drevets, W. C., and Furey, M. L. (2010). Replication of Scopolamine's Antidepressant Efficacy in Major Depressive Disorder: a Randomized, Placebo-Controlled Clinical Trial. Biol. Psychiatry 67 (5), 432–438. doi:10.1016/j.biopsych.2009.11.021

Fava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., et al. (2016). Opioid Modulation with Buprenorphine/samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. Am. J. Psychiatry 173 (5), 499–508. doi:10.1176/appi.ajp.2015.15070921

Fava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., et al. (2022). REL-1017 (Esmethadone) as Adjunctive Treatment in Patients with Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. Am. J. Psychiatry 179 (2), 122–131. doi:10.1176/appi.ajp.2021.21020197

Fava, M., Thase, M. E., Trivedi, M. H., Ehrich, E., Martin, W. F., Memisoglu, A., et al. (2020). Opioid System Modulation with Buprenorphine/samidorphan Combination for Major Depressive Disorder: Two Randomized Controlled Studies. Mol. Psychiatry 25 (7), 1580–1591. doi:10.1038/s41386-018-0284-1

Finzi, E., and Rosenthal, N. E. (2014). Treatment of Depression with Olanzapine and Pimozide: A Randomized, Double-Blind, Placebo-Controlled Trial. J. Psychopharmacol. 28 (1), 1–6. doi:10.1177/0269704313510806

Fogaça, M. V., Fukumoto, K., Franklin, T., Liu, R. J., Duman, C. H., Vito, O. V., et al. (2019). N-Methyl-D-aspartate Receptor Antagonist D-Methadone Produces rapid, mTORMC-dependent Antidepressant Effects. Neuroperopharmacology 44 (13), 2230–2238. doi:10.1016/j.neuropharm.2019.0501-x

Fried, I. E., and Nesse, R. M. (2014). The Impact of Individual Depression Symptoms on Impairment of Psychosocial Functioning. PLoS One 9 (2), e90311. doi:10.1371/journal.pone.0090311

Frye, M. A., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Speer, A. M., Osuch, E. A., et al. (2000). A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders. J. Clin. Psychopharmacol. 20 (6), 607–614. doi:10.1097/00004714-200012000-00004

Furey, M. L., and Drevets, W. C. (2006). Antidepressant Efficacy of the Antimuscarinic Drug Scopolamine: A Randomized, Placebo-Controlled Clinical Trial. Arch. Gen. Psychiatry 63 (10), 1121–1129. doi:10.1001/archpsyc.63.10.1121

Gant, T. G. (2014). Using Deuterium in Drug Discovery: Leaving the Label in the Drug. J. Med. Chem. 57 (9), 3595–3611. doi:10.1021/jm5007998

Ghaemi, N., Svedlov, A., Shelton, R., and Litman, R. (2021). Efficacy and Safety of MIL3821 in Patients with Treatment-Resistant Depression: Results from a Randomized, Placebo-Controlled, Proof-Of-Concept Study. Eur. Psychiatr. 64 (51), S334–S335. doi:10.1192/eurpsy.2021.897

Hara, H., Suzuki, A., Kunugi, A., Tajima, Y., Yamada, R., and Kimura, H. (2021). TAC-653, an AMPA Receptor Potentiator with Minimal Agonistic Activity, Produces an Antidepressant-like Effect with a Favorable Safety Profile in Rats. Pharmacol. Biochem. Behav. 211, 173289. doi:10.1016/j.pbb.2021.173289

Hecking, J., Davoudian, P. A., and Wilkinson, S. T. (2021). Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders. Chronic Stress (Thousand Oaks) 5, 2470547021102046. doi:10.1371/journal.pone.0090311

Heerlein, K., De Giorgi, S., Deagreave, G., Frodl, T., Hagedorn, W., Oliveira-Maia, A. J., et al. (2022). Real-world Evidence from a European Cohort Study of Patients with Treatment-Resistant Depression: Healthcare Resource Utilization. J. Affect. Disord. 298 (Pt), 442–450. doi:10.1016/j.jad.2021.11.004

Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., et al. (2013). Produces an Enhanced Addictive-Reducing Effect with a Favorable Safety Profile in Rats. Pharmacol. Biochem. Behav. 211, 173289. doi:10.1016/j.pbb.2021.173289

Huang, C. C., Wei, I. H., Huang, C. L., Chen, K. T., Tsai, M. H., Tsai, P., et al. (2013). Inhibition of glycine transporter-1 as a Novel Mechanism for the Treatment of Depression. Biol. Psychiatry 74 (10), 734–741. doi:10.1016/j.biopsych.2013.02.020

Ibrahim, L., Diaz Granados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., et al. (2012). A Randomized, Placebo-Controlled, Crossover
Menke, A. (2019). Is the HPA axis as Target for Depression Outdated, or Is There a
Frontiers in Pharmacology | www.frontiersin.org June 2022 | Volume 13 | Article 884155
Vasiliu Antidepressants in the Pipeline (II)
Mathew, S. J., Murrough, J. W., aan het Rot, M., Collins, K. A., Reich, D. L., and
Monti, L., Nicolini, H., Liebowitz, M. R., and Hanover, R. (2019). A Placebo
Controlled Trial of PH10: Test for a New Rapidly Acting Intranasally
Administered Antidepressant. Br. J. Pharm. Med. Res. 4 (6), 2157–2168.
doi:10.24942/bjpmr.2019.604
Moskal, J. R., Burch, R., Burgdorf, J. S., Kroes, R. A., Stanton, P. K., Disterhof, J. F., et al. (2014). GLYX-13, an NMDA Receptor glycine Site Functional
Partial Agonist Enhances Cognition and Produces Antidepressant Effects
without the Psychotomimetic Side Effects of NMDA Receptor Antagonists.
Expert Opin. Investig. Drugs 23 (2), 243–254. doi:10.1517/13543784.2014.852536
Murphy, N., Ramakrishnan, N., Vo-Le, B., Vo-Le, B., Smith, M. A., Iqbal, T., et al. (2021). A Randomized Cross-Over Trial to Define Neuropsychiological Correlates
of AV-101 N-Methyl-D-Aspartate Receptor Blockade in Healthy Veterans.
Neuropsychopharmacology 46 (4), 820–827. doi:10.1038/s41386-020-00917-x
Murrough, J. W., Wade, E., Sayed, S., Ahile, G., Kiraly, D. D., Welch, A., et al. (2017). Dextromethorphan/quinidine Pharmacotherapy in Patients with
Treatment Resistant Depression: A Proof of Concept Clinical Trial. J. Affect
Disord. 218, 277–283. doi:10.1016/j.jad.2017.04.072
Nagel, P., Duma, A., Kopeck, M., Gebara, M. A., Parsoei, A., Walker, M., et al. (2015). Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-Of-
Concept Trial. Biol. Psychiatry 78 (1), 10–18. doi:10.1016/j.biopsycho.2014.11.016
National Library of Medicine U.S (2010a). 6-week Study Treatment to Evaluate the
Safety and Effectiveness of AZD2006 in Patients with Major Depressive
Disorder. Available at: https://clinicaltrials.gov/ct2/show/NCT01145755
(Accessed February 3, 2022).
National Library of Medicine U.S (2006a). A Double-Blind Placebo-Controlled
Trial of Riluzole in Bipolar Depression. Available at: https://clinicaltrials.gov/
ct2/show/results/NCT00736220 (Accessed April 4, 2022).
National Library of Medicine U.S (2017a). A Study of ALKS-5461 for the Treatment
Refractory Major Depression Disorder (MDD). Available at: https://clinicaltrials.gov/
c/bct/show/results/NCT03188185 (Accessed February 4, 2022).
National Library of Medicine U.S (2014a). A Study of Different Titration Schedules
of ALKS-5461 in Adults with Major Depressive Disorder (MDD). Available at: http://clinicaltrials.gov/ct2/show/results/NCT02085135 (Accessed February 4, 2022).
National Library of Medicine U.S (2015a). A Study of Safety, Tolerability, and
Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects
and in Patients with Major Depressive Disorder (MDD). Available at: https://clinicaltrials.gov/ct2/show/NCT02433093 (Accessed January 30, 2022).
National Library of Medicine U.S (2020). A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults with Major Depressive Disorder at Imminent Risk of Suicide. Available at: https://clinicaltrials.gov/ct2/show/NCT04696965
(Accessed February 5, 2022).
National Library of Medicine U.S (2011a). A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT). Available at: https://clinicaltrials.gov/ct2/show/NCT01312844 (Accessed April 2, 2022).
National Library of Medicine U.S (2021a). A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (RELIANCE-I). Available at: https://clinicaltrials.gov/ct2/show/NCT05081167 (Accessed February 3, 2022).
National Library of Medicine U.S (2021b). A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (RELIANCE-II). Available at: https://clinicaltrials.gov/ct2/show/NCT04855747. Accessed February 3, 2022.
National Library of Medicine U.S (2021c). A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) (RELIANCE-III). Available at: https://clinicaltrials.gov/ct2/show/NCT05081167 (Accessed February 3, 2022).
National Library of Medicine U.S (2017b). A Study to Investigate the Safety,
Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects (SUVN-911). Available at: https://clinicaltrials.gov/ct2/show/NCT03155503 (Accessed February 5, 2022).
National Library of Medicine U.S (2018b). AGN-241751 in the Treatment of Major
Depressive Disorder. Available at: https://clinicaltrials.gov/ct2/show/
NCT03726658 (Accessed January 30, 2022).
National Library of Medicine U.S (2021d). Antidepressant Effects of TS-161 in Treatment-Resistant Depression. Available at: https://clinicaltrials.gov/ct2/show/
NCT04821271 (Accessed February 3, 2022).
in Mood Disorders Based on Glutamate/GABA Neurotransmitter Systems. Drug Discov. Today 24 (2), 606–615. doi:10.1016/j.drudis.2018.11.007
Yang, C., Shirayama, Y., Zhang, J. C., Ren, Q., Yao, W., Ma, M., et al. (2015). R-ketamine: a Rapid-Onset and Sustained Antidepressant without Psychotomimetic Side Effects. Transl Psychiatry 5 (9), e632. doi:10.1038/tp.2015.136
Zajecka, J. M., Stanford, A. D., Memisoglu, A., Martin, W. F., and Pathak, S. (2019). Buprenorphine/samidorphan Combination for the Adjunctive Treatment of Major Depressive Disorder: Results of a Phase III Clinical Trial (FORWARD-3). Neuropsychiatr. Dis. Treat. 15, 795–808. doi:10.2147/NDT.S199245
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., et al. (2016). NMDAR Inhibition-independent Antidepressant Actions of Ketamine Metabolites. Nature 533 (7604), 481–486. doi:10.1038/nature17998
Zanos, P., Piantadosi, S. C., Wu, H. Q., Pribut, H. J., Dell, M. J., Can, A., et al. (2015). The Prodrug 4-chlorokynurenine Causes Ketamine-like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-site Inhibition. J. Pharmacol. Exp. Ther. 355 (1), 76–85. doi:10.1124/jpet.115.225664
Zarate, C. A., Jr, Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., et al. (2013). A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression. Biol. Psychiatry 74 (4), 257–264. doi:10.1016/j.biopsych.2012.10.019
Zarate, C. A., Jr., Payne, J. L., Quiroz, J., Sporn, J., Denicoff, K. K., Luckenbaugh, D., et al. (2004). An Open-Label Trial of Riluzole in Patients with Treatment-Resistant Major Depression. Am. J. Psychiatry 161, 171–174. doi:10.1176/appi.ajp.161.1.171
Zarate, C. A., Jr., Quiroz, J. A., Singh, J. B., Denicoff, K. D., De Jesus, G., Luckenbaugh, D. A., et al. (2005). An Open-Label Trial of the Glutamate-Modulating Agent Riluzole in Combination with Lithium for the Treatment of Bipolar Depression. Biol. Psychiatry 57 (4), 430–432. doi:10.1016/j.biopsych.2004.11.023
Zarate, C. A., Jr., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., et al. (2006). A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression. Am. J. Psychiatry 163 (1), 153–155. doi:10.1176/appi.ajp.163.1.153
Zhang, J. C., Li, S. X., and Hashimoto, K. (2014). R (-)-ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than S (+)-ketamine. Pharmacol. Biochem. Behav. 116, 137–141. doi:10.1016/j.pbb.2013.11.033
Zhang, X. C., Farrell, N., Haronian, T., and Hack, J. (2017). Postoperative Anticholinergic Poisoning: Concealed Complications of a Commonly Used Medication. J. Emerg. Med. 53 (4), 520–523. doi:10.1016/j.jemermed.2017.05.003
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., et al. (2000). Effects of the High-Affinity Corticotropin-Releasing Hormone Receptor 1 Antagonist R121919 in Major Depression: the First 20 Patients Treated. J. Psychiatr. Res. 34 (3), 171–181. doi:10.1016/s0022-3956(00)00016-9

Conflict of Interest: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Vasiliu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.